Revelation Biosciences (REVB) S-1/A 30 Jan 24 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2023
Document Information Line Items
Entity Registrant Name	REVELATION BIOSCIENCES, INC.
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 2
Entity Central Index Key	0001810560
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,994,537	$ 5,252,979	$ 1,274,729
Deferred offering costs		87,171
Prepaid expenses and other current assets	152,637	73,132	637,342
Total current assets	14,147,174	5,413,282	1,912,071
Property and equipment, net	71,346	90,133	115,181
Right-of-use lease asset			14,960
Total assets	14,218,520	5,503,415	2,042,212
Current liabilities:
Accounts payable	1,257,224	554,205	596,261
Accrued expenses	1,022,035	985,497	1,528,669
Lease liability			16,752
Deferred underwriting commissions	2,911,260	2,911,260
Warrant liability	209,478
Total current liabilities	5,399,997	4,450,962	2,141,682
Total liabilities	5,399,997	4,450,962	2,141,682
Stockholders’ equity (deficit):
Additional paid-in-capital	32,076,425	26,398,618	14,417,547
Accumulated deficit	(23,264,199)	(25,346,848)	(14,517,299)
Total stockholders’ equity	8,818,523	1,052,453	(99,470)
Total liabilities and stockholders’ equity	14,218,520	5,503,415	2,042,212
Series A Preferred Stock
Stockholders’ equity (deficit):
Preferred stock value
Revelation Sub Series A Preferred Stock
Stockholders’ equity (deficit):
Preferred stock value
Revelation Sub Series A-1 Preferred Stock
Stockholders’ equity (deficit):
Preferred stock value
Common Stock
Stockholders’ equity (deficit):
Common stock value	$ 6,297	$ 683	$ 282

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Series A Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares outstanding	0	1	0
Preferred stock, shares authorized	0	1	0
Preferred stock, shares issued	0	1	0
Preferred stock, liquidation preference (in Dollars)	$ 0	$ 5,000	$ 0
Revelation Sub Series A Preferred Stock
Preferred stock, par value (in Dollars per share)		$ 0.001	$ 0.001
Preferred stock, shares outstanding		0	0
Preferred stock, shares authorized		0	0
Preferred stock, shares issued		0	0
Revelation Sub Series A-1 Preferred Stock
Preferred stock, par value (in Dollars per share)		$ 0.001	$ 0.001
Preferred stock, shares outstanding		0	0
Preferred stock, shares authorized		0	1,100,000
Preferred stock, shares issued		0	0
Common Stock
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	11,000,000
Common stock, shares outstanding	6,297,303	682,882	282,039
Common Stock, shares issued	6,297,303	682,882	282,039

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 1,651,367	$ 381,566	$ 3,085,918	$ 5,037,429	$ 5,377,400	$ 6,914,756
General and administrative	1,126,530	817,898	3,244,856	4,608,755	5,487,111	5,035,729
Total operating expenses	2,777,897	1,199,464	6,330,774	9,646,184	10,864,511	11,950,485
Loss from operations	(2,777,897)	(1,199,464)	(6,330,774)	(9,646,184)	(10,864,511)	(11,950,485)
Other income (expense):
Change in fair value of warrant liability	92,561		8,260,735
Other income (expense)	56,960	28,728	152,688	24,221	34,962	(36,352)
Total other income (expense), net	149,521	28,728	8,413,423	24,221	34,962	(36,352)
Net (loss) income	$ (2,628,376)	$ (1,170,736)	$ 2,082,649	$ (9,621,963)	$ (10,829,549)	$ (11,986,837)
Net (loss) earnings per share, basic (in Dollars per share)	$ (0.42)	$ (1.91)	$ 0.43	$ (19.61)	$ (20.09)	$ (42.5)
Weighted-average shares used to compute net (loss) earnings per share, basic (in Shares)	6,297,303	611,998	4,857,628	490,562	539,037	282,035
Net (loss) earnings per share, diluted (in Dollars per share)	$ (0.42)	$ (1.91)	$ 0.41	$ (19.61)	$ (20.09)	$ (42.50)
Weighted-average shares used to compute net (loss) earnings per share, diluted (in Shares)	6,297,303	611,998	5,024,091	490,562	539,037	282,035

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net loss per share, diluted	$ (0.42)	$ (1.91)	$ 0.41	$ (19.61)	$ (20.09)	$ (42.50)
Weighted-average shares used to compute net loss per share, diluted	6,297,303	611,998	5,024,091	490,562	539,037	282,035

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)	Business Combination Previously Reported Series A Preferred Stock	Business Combination Previously Reported Series A-1 Preferred Stock	Business Combination Previously Reported Common Stock	Business Combination Previously Reported Additional Paid-in Capital	Business Combination Previously Reported Accumulated Deficit	Business Combination Previously Reported	Business Combination Series A Preferred Stock	Business Combination Series A-1 Preferred Stock	Business Combination Common Stock	Business Combination Additional Paid-in Capital	Business Combination Accumulated Deficit	Business Combination	Previously Reported Series A Preferred Stock	Previously Reported Series A-1 Preferred Stock	Previously Reported Common Stock	Previously Reported Additional Paid-in Capital	Previously Reported Accumulated Deficit	Previously Reported	Series A Preferred Stock	Series A-1 Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019													$ 403,733		$ 66	$ 5,538,287	$ (2,530,462)	$ 3,411,624
Balance (in Shares) at Dec. 31, 2019													628,930		65,519
Retrospective application of reverse recapitalization													$ (3,903,730)	$ (3,578,197)	$ 206	7,481,721
Reverse stock split fractional stock round up															10	(10)
Balance at Dec. 31, 2020	$ (3,499,997)	$ (3,578,197)	$ 282	$ 13,019,998	$ (2,530,462)	$ 3,411,624							$ 3,903,730	$ 3,578,197	$ 66	6,935,836	(14,517,299)	(99,470)
Balance (in Shares) at Dec. 31, 2020		(684,450)	281,589										628,930	684,450	65,969
Retrospective application of reverse recapitalization (in Shares)													(628,930)	(684,450)	205,658
Reverse stock split fractional stock round up (in Shares)															10,412
Repurchase for the Forward Share Purchase Agreement exercise
Issuance of common stock																						$ 99,998		99,998
Issuance of common stock (in Shares)																					450
Issuance of Revelation Sub Series A-1 Preferred Stock, net																				$ 3,904,872				3,904,872
Issuance of Revelation Sub Series A-1 Preferred Stock, net (in Shares)																				684,450
Issuance of Warrants in connection with the issuance of the Revelation Sub Series A-1 Preferred Stock																				$ (326,675)		326,675
Payment for Revelation Sub Series A Preferred Stock subscribed																			3,499,997					3,499,997
Payment for common stock subscribed																						499,998		499,998
Stock-based compensation expense																						470,878		470,878
Net income (loss)																							(11,986,837)	(11,986,837)
Retrospective application of reverse recapitalization													$ (3,903,730)	$ (3,578,197)	$ 206	7,481,721
Reverse stock split fractional stock round up															$ 10	$ (10)
Balance at Dec. 31, 2021			$ 282	14,417,547	(14,517,299)	(99,470)			$ 282	$ 14,417,547	$ (14,517,299)	$ (99,470)									$ 282	14,417,547	(14,517,299)	(99,470)
Balance (in Shares) at Dec. 31, 2021			282,039						282,039												282,039
Retrospective application of reverse recapitalization (in Shares)													(628,930)	(684,450)	205,658
Reverse stock split fractional stock round up (in Shares)															10,412
Issuance of common stock in connection with the Business Combination, net																					$ 98	6,864,229		6,864,327
Issuance of common stock in connection with the Business Combination, net (in Shares)																					98,209
Issuance of common stock for fees in connection with the Business Combination																					$ 9	291		300
Issuance of common stock for fees in connection with the Business Combination (in Shares)																					8,572
Proceeds from the PIPE Investment, net																					$ 37	7,262,182		7,262,219
Proceeds from the PIPE Investment, net (in Shares)																					36,947
Rollover Warrant exercise																						5,074		5,074
Rollover Warrant exercise (in Shares)																					54
Repurchase for the Forward Share Purchase Agreement exercise																					$ (21)	(7,652,304)		(7,652,325)
Repurchase for the Forward Share Purchase Agreement exercise (in Shares)																					(21,429)
Stock-based compensation expense																						137,892		137,892
Net income (loss)																							(6,616,541)	(6,616,541)
Class A Pre-Funded Warrants exercise																					$ 37	(24)		13
Class A Pre-Funded Warrants exercise (in Shares)																					36,959
Balance at Mar. 31, 2022																					$ 442	21,034,887	(21,133,840)	(98,511)
Balance (in Shares) at Mar. 31, 2022																					441,351
Balance at Dec. 31, 2021			$ 282	14,417,547	(14,517,299)	(99,470)			$ 282	14,417,547	(14,517,299)	(99,470)									$ 282	14,417,547	(14,517,299)	(99,470)
Balance (in Shares) at Dec. 31, 2021			282,039						282,039												282,039
Repurchase for the Forward Share Purchase Agreement exercise																								(7,652,325)
Net income (loss)																								(9,621,963)
Balance at Sep. 30, 2022																					$ 683	26,366,257	(24,139,262)	2,227,678
Balance (in Shares) at Sep. 30, 2022																					682,882
Balance at Dec. 31, 2021			$ 282	$ 14,417,547	$ (14,517,299)	$ (99,470)			$ 282	$ 14,417,547	$ (14,517,299)	$ (99,470)									$ 282	14,417,547	(14,517,299)	(99,470)
Balance (in Shares) at Dec. 31, 2021			282,039						282,039												282,039
Issuance of common stock in connection with the Business Combination, net																					$ 98	6,864,229		6,864,327
Issuance of common stock in connection with the Business Combination, net (in Shares)																					98,209
Issuance of common stock for fees in connection with the Business Combination																					$ 9	291		300
Issuance of common stock for fees in connection with the Business Combination (in Shares)																					8,572
Proceeds from the PIPE Investment, net																					$ 37	7,262,182		7,262,219
Proceeds from the PIPE Investment, net (in Shares)																					36,947
Rollover Warrant exercise																						5,074		5,074
Rollover Warrant exercise (in Shares)																					54
Repurchase for the Forward Share Purchase Agreement exercise																					$ (21)	(7,652,304)		(7,652,325)
Repurchase for the Forward Share Purchase Agreement exercise (in Shares)																					(21,429)
Pre-Funded Warrants exercise																					$ 37	(24)		13
Pre-Funded Warrants exercise (in Shares)																					36,959
Proceeds from the July 2022 Public Offering, net																					$ 238	4,450,810		4,451,048
Proceeds from the July 2022 Public Offering, net (in Shares)																					238,096
RSU awards issued																					$ 3	(3)
RSU awards issued (in Shares)																					3,435
Issuance of common stock for Accrued Expenses in connection with the Business Combination																						749,700		749,700
Issuance of Series A Preferred Stock
Issuance of Series A Preferred Stock (in Shares)																			1
Stock-based compensation expense																						301,116		301,116
Net income (loss)																							(10,829,549)	(10,829,549)
Balance at Dec. 31, 2022																					$ 683	26,398,618	(25,346,848)	1,052,453
Balance (in Shares) at Dec. 31, 2022																			1		682,882
Balance at Mar. 31, 2022																					$ 442	21,034,887	(21,133,840)	(98,511)
Balance (in Shares) at Mar. 31, 2022																					441,351
Stock-based compensation expense																						90,188		90,188
Net income (loss)																							(1,834,686)	(1,834,686)
Balance at Jun. 30, 2022																					$ 442	21,125,075	(22,968,526)	(1,843,009)
Balance (in Shares) at Jun. 30, 2022																					441,351
Proceeds from the July 2022 Public Offering, net																					$ 238	4,450,810		4,451,048
Proceeds from the July 2022 Public Offering, net (in Shares)																					238,096
RSU awards issued																					$ 3	(3)
RSU awards issued (in Shares)																					3,435
Issuance of common stock for Accrued Expenses in connection with the Business Combination																						749,700		749,700
Stock-based compensation expense																						40,675		40,675
Net income (loss)																							(1,170,736)	(1,170,736)
Balance at Sep. 30, 2022																					$ 683	26,366,257	(24,139,262)	2,227,678
Balance (in Shares) at Sep. 30, 2022																					682,882
Balance at Dec. 31, 2022																					$ 683	26,398,618	(25,346,848)	1,052,453
Balance (in Shares) at Dec. 31, 2022																			1		682,882
Stock-based compensation expense																						32,095		32,095
Net income (loss)																							6,159,195	6,159,195
Redemption of Series A Preferred Stock
Redemption of Series A Preferred Stock (in Shares)																			(1)
Issuance of common stock from the February 2023 Public Offering																					$ 2,889	30,585		33,474
Issuance of common stock from the February 2023 Public Offering (in Shares)																					2,888,600
Class C Pre-Funded Warrants exercise																					$ 193	(174)		19
Class C Pre-Funded Warrants exercise (in Shares)																					193,000
Alternative cashless exercise of Class C Common Stock Warrants																					$ 965	2,739,445		2,740,410
Alternative cashless exercise of Class C Common Stock Warrants (in Shares)																					965,357
Balance at Mar. 31, 2023																					$ 4,730	29,200,569	(19,187,653)	10,017,646
Balance (in Shares) at Mar. 31, 2023																					4,729,839
Balance at Dec. 31, 2022																					$ 683	26,398,618	(25,346,848)	1,052,453
Balance (in Shares) at Dec. 31, 2022																			1		682,882
Net income (loss)																								2,082,649
Balance at Sep. 30, 2023																					$ 6,297	32,076,425	(23,264,199)	8,818,523
Balance (in Shares) at Sep. 30, 2023																					6,297,303
Balance at Mar. 31, 2023																					$ 4,730	29,200,569	(19,187,653)	10,017,646
Balance (in Shares) at Mar. 31, 2023																					4,729,839
RSU awards issued																					$ 4	(4)
RSU awards issued (in Shares)																					4,284
Stock-based compensation expense																						59,435		59,435
Net income (loss)																							(1,448,170)	(1,448,170)
Class C Pre-Funded Warrants exercise																					$ 143	(128)		15
Class C Pre-Funded Warrants exercise (in Shares)																					143,400
Alternative cashless exercise of Class C Common Stock Warrants																					$ 1,420	2,784,457		2,785,877
Alternative cashless exercise of Class C Common Stock Warrants (in Shares)																					1,419,780
Balance at Jun. 30, 2023																					$ 6,297	32,044,329	(20,635,823)	11,414,803
Balance (in Shares) at Jun. 30, 2023																					6,297,303
Stock-based compensation expense																						32,096		32,096
Net income (loss)																							(2,628,376)	(2,628,376)
Balance at Sep. 30, 2023																					$ 6,297	$ 32,076,425	$ (23,264,199)	$ 8,818,523
Balance (in Shares) at Sep. 30, 2023																					6,297,303

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net income (loss)	$ 2,082,649	$ (9,621,963)	$ (10,829,549)	$ (11,986,837)
Stock-based compensation expense	123,626	268,755	301,116	470,878
Depreciation expense	18,787	18,786	25,048	16,782
Non-cash lease expense		14,960	14,960	52,384
Change in fair value of warrant liability	(8,260,735)
Prepaid expenses and other current assets	(79,505)	332,548	569,044	(509,342)
Deferred offering costs	61,154		(61,154)
Accounts payable	720,936	(736,246)	(666,042)	(269,640)
Accrued expenses	49,638	(568,937)	(592,987)	1,185,794
Operating lease liability		(16,752)	(16,752)	(50,592)
Accrued interest on Promissory Notes Payable & Convertible Note		36,920	36,920
Net cash used in operating activities	(5,283,450)	(10,271,929)	(11,219,396)	(11,090,573)
Cash flows from investing activities:
Purchase of property and equipment				(131,963)
Net cash used in investing activities				(131,963)
Cash flows from financing activities:
Proceeds from the Convertible Note		2,500,000	2,500,000
Repayment of the Convertible Note		(2,500,000)	(2,500,000)
Proceeds from the Business Combination, net		11,923,499	11,923,499
Proceeds from the PIPE Investment, net		7,262,219	7,262,219
Redemption of Series A Preferred Stock	(5,000)
Proceeds from issuance of common stock, net				599,996
Net cash provided by financing activities	14,025,008	15,192,646	15,197,646	8,004,865
Repurchase for the Forward Share Purchase Agreement exercise		(7,652,325)	(7,652,325)
Repayments of Promissory Notes Payable, including interest		(796,882)	(796,882)
Net increase in cash and cash equivalents	8,741,558	4,920,717	3,978,250	(3,217,671)
Cash and cash equivalents at beginning of period	5,252,979	1,274,729	1,274,729	4,492,400
Cash and cash equivalents at end of period	13,994,537	6,195,446	5,252,979	1,274,729
Supplemental disclosure of non-cash investing and financing activities:
Deferred offering costs included in accounts payable and accrued expenses	(26,017)		26,017
Alternative cashless exercise of Class C Common Stock Warrants	5,526,287
Current liabilities assumed in the Business Combination		2,149,432	2,149,432
Deferred underwriting commissions assumed in the Business Combination		2,911,260	2,911,260
Equity Issuance for fees in connection with the Business Combination		300	300
Issuance of Class A Common Stock Warrants in connection with the PIPE Investment		3,634,262	3,634,262
Issuance of Class A Placement Agent Common Stock Warrants in connection with the PIPE Investment		508,797	508,797
Conversion of Accrued Expenses to Equity in connection with the Business Combination		749,700	749,700
Issuance of Class B Common Stock Warrants in connection with the July 2022 Public Offering		4,490,457	4,490,457
Issuance of Class B Placement Agent Common Stock Warrants in connection with the July 2022 Public Offering		310,137	310,137
Acquisition of right-of-use asset through operating lease obligation				67,344
Issuance of warrants in connection with Revelation Sub Series A-1 Preferred Stock				326,675
July 2022 Public Offering
Cash flows from financing activities:
Proceeds from the Public Offering, net		4,451,048	4,451,048
February 2023 Public Offering
Cash flows from financing activities:
Proceeds from the Public Offering, net	14,029,974
Rollover Warrant
Cash flows from financing activities:
Proceeds from Warrant exercise		5,074	5,074
Pre-Funded Warrants
Cash flows from financing activities:
Proceeds from Warrant exercise	34	$ 13	13
Series A Preferred Stock
Cash flows from financing activities:
Proceeds from issuance of Preferred Stock, net			5,000	3,499,997
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series A Preferred Stock to common stock			3,903,730
Series A-1 Preferred Stock
Cash flows from financing activities:
Proceeds from issuance of Preferred Stock, net				3,904,872
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series A Preferred Stock to common stock			$ 3,578,197
Class C Common Stock
Supplemental disclosure of non-cash investing and financing activities:
Fair Value of Class C Common Stock Warrants in connection with the February 2023 Public Offering	$ 13,996,500

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Organization and Basis of Presentation [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Revelation Biosciences, Inc. (collectively with its wholly -owned -stage Business Combination The Business Combination was accounted for as a reverse recapitalization with Revelation Sub as the accounting acquirer and Petra as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Revelation Sub as if Revelation Sub is the predecessor to the Company. The common stock and net loss per share, prior to the Merger, have been retroactively restated as common stock and net loss per share reflecting the exchange ratio established in the Business Combination (the “Common Stock Exchange Ratio”). Petra’s Common Stock, Public Warrants and Units were historically listed on the Nasdaq Capital Market under the symbols “PAIC,” “PAICW” and “PAICU,” respectively. On January 10, 2022, the Company’s units, common stock and warrants were listed on the Nasdaq Capital Market under the symbols “REVBU”, “REVB” and “REVBW”, respectively.- Unit Separation On January 13, 2023, the Company’s units were mandatorily separated into one share of common stock and one Public Warrant and ceased trading on the Nasdaq Capital Market (see Note 9). Reverse Stock Split On January 30, 2023, the Company filed a Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) reflecting the change in authorized shares of common stock from 100,000,000 to 500,000,000 and effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on February 1, 2023 with a ratio of 1 -for-35 -outstanding -for-35 NASDAQ Compliance As previously reported in 2022, the Nasdaq Stock Market (“Nasdaq”) issued delist letters based on the Company’s non -compliance As previously reported on August 8, 2023, the Company received a letter from the Nasdaq notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) by failing to maintain a minimum bid price for its common stock of at least $1.00 per share for 30 consecutive business days. The Company has until February 5, 2024, to regain compliance by having a minimum closing bid price of at least $1.00 per share for at least 10 consecutive business days. Additionally, the Company may be eligible for an additional 180 calendar day grace period to regain compliance. Liquidity and Capital Resources Going Concern As of September 30, 2023, the Company had an accumulated deficit of $23.3 million, a stockholders’ equity of $8.8 million and available cash and cash equivalents of $14.0 million. The Company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to complete all necessary product development or future commercialization efforts. The Company has never generated revenue and does not expect to generate revenue from product sales unless and until it successfully completes development and obtains regulatory approval for REVTx -300 -100 -200 -99b -501 To continue as a going concern, the Company will need, among other things, to raise additional capital resources. The Company plans to seek additional funding through public or private equity or debt financings. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect the Company’s business operations. The unaudited consolidated financial statements for September 30, 2023, have been prepared on the basis that the Company will continue as a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability for the Company to continue as a going concern. Basis of Presentation The accompanying financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All inter -company	1. Organization and Basis of Presentation Revelation Biosciences, Inc. (collectively with its wholly -owned -stage The Business Combination was accounted for as a reverse recapitalization with Revelation Sub as the accounting acquirer and Petra as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the audited consolidated financial statements represents the accounts of Revelation Sub as if Revelation Sub is the predecessor to the Company. The common stock and net loss per share, prior to the Merger, have been retroactively restated as common stock and net loss per share reflecting the exchange ratio established in the Business Combination (the “Common Stock Exchange Ratio”). Petra’s Common Stock, Public Warrants and Units were historically listed on the Nasdaq Capital Market under the symbols “PAIC,” “PAICW” and “PAICU,” respectively. On January 10, 2022, the Company’s units, common stock and warrants were listed on the Nasdaq Capital Market under the symbols “REVBU”, “REVB” and “REVBW”, respectively, (see Note 3). On January 13, 2023, the Company’s units were mandatorily separated into one share of common stock and one Public Warrant and ceased trading on the Nasdaq Capital Market. On January 30, 2023, the Company filed a Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) reflecting the change in authorized shares of common stock from 100,000,000 to 500,000,000 and effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on February 1, 2023 with a ratio of 1 -for-35 -outstanding -for-35 The Company has incurred recurring losses since its inception, including a net loss of $10.8 million for the year ended December 31, 2022. As of December 31, 2022, the Company had an accumulated deficit of $25.3 million, a stockholders’ equity of $1.1 million and available cash and cash equivalents of $5.3 million. The Company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to complete all necessary product development or future commercialization efforts. The Company has never generated revenue and does not expect to generate revenue from product sales unless and until it successfully completes development and obtains regulatory approval for REVTx -300 -100 -200 -99b -501 To continue as a going concern, the Company will need, among other things, to raise additional capital resources. The Company plans to seek additional funding through public or private equity or debt financings. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect the Company’s business operations. The audited consolidated financial statements for December 31, 2022, have been prepared on the basis that the Company will continue as a going concern, and does not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability for the Company to continue as a going concern. The accompanying financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). All inter -company

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Unaudited Interim Condensed Consolidated Financial Statements The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements as of December 31, 2022 and for the year ended December 31, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2023 are unaudited. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included on Form 10 -K -K Use of Estimates The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s condensed consolidated financial statements. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. The Company maintains its cash in checking and savings accounts. Income generated from cash held in savings accounts is recorded as interest income. The carrying value of the Company’s savings accounts is included in cash and approximates the fair value. Concentrations of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents. Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third -party -process Property and Equipment, Net Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight -line five Leases The Company determines if an arrangement is a lease at inception. Lease right -of-use -of-use -of-use -line Research and Development Expenses Research and development expenses consist primarily of costs incurred for the development of the Company’s product candidates, REVTx -300 -100 -200 -99a -501 Patent Costs Legal costs in connection with approved patents and patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are recorded in general and administrative expense in the condensed consolidated statements of operations. Stock-based Compensation The Company recognizes compensation expense related to stock options, third -party -based -party -Scholes -pricing -free dividends. The grant date fair value of the stock -based -line -based -based Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or loss in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Interest and penalties related to unrecognized tax benefits are included within the provision of income tax. To date, there have been no unrecognized tax benefits balances. Fair Value Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company follows a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. These levels of inputs are the following: • • • The Company has determined that the measurement of the fair value of the Class C Common Stock Warrants (as defined in Note 7) is a Level 3 fair value measurement and uses the Monte -Carlo Warrant Liability The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants. The Company accounts for its common stock warrants in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as current liabilities if the warrant fails the equity classification criteria. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liabilities within the condensed consolidated statements of operations. The Company values its common stock warrants classified as liabilities using either the Black -Scholes -Carlo Basic and Diluted Net (Loss) Earnings per Share Basic net (loss) earnings per share is calculated by dividing net (loss) income by the weighted -average -average -dilutive For the three months ended September 30, 2023, there were 1,169,255 potential shares of common stock, (see Note 10), that were excluded from the calculation of diluted net loss per share because their effect was anti -dilutive -dilutive The basic and diluted weighted -average Comprehensive (Loss) Income The Company has no components of comprehensive (loss) income other than net (loss) income. Thus, comprehensive (loss) income is the same as net (loss) income for the periods presented. Segment Reporting Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations for the purposes of allocating resources and evaluating financial performance. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Company’s condensed consolidated financial statements or related financial statement disclosures.	2. Summary of Significant Accounting Policies Use of Estimates The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s consolidated financial statements. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. The Company maintains its cash in checking and savings accounts. Income generated from cash held in savings accounts is recorded as interest income. The carrying value of the Company’s savings accounts is included in cash and approximates the fair value. Concentrations of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents. Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third -party -process Property and Equipment, Net Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight -line five Leases The Company determines if an arrangement is a lease at inception. Lease right -of-use -of-use -of-use -line Research and Development Expenses Research and development expenses consist primarily of costs incurred for the development of the Company’s product candidates, REVTx -300 -100 -200 -99a -501 Patent Costs Legal costs in connection with approved patents and patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are recorded in general and administrative expense in the statements of operations. Stock-based Compensation The Company recognizes compensation expense related to stock options, third -party -based -party -Scholes -pricing -free dividends. The grant date fair value of the stock -based -line -based -based Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or loss in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Interest and penalties related to unrecognized tax benefits are included within the provision of income tax. To date, there have been no Basic and Diluted Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted -average -average -dilutive -dilutive -average Comprehensive Loss The Company has no components of comprehensive loss other than net loss. Thus, comprehensive loss is the same as net loss for the periods presented. Segment Reporting Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations for the purposes of allocating resources and evaluating financial performance. Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019 -12 Simplifying the Accounting for Income Taxes (Topic 740) (“ASU 2019 -12 ”). -12 -period interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. This guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within the fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company’s adoption of the ASU 2019 -12

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2022
Business Combination [Abstract]
Business Combination	3. Business Combination As disclosed in Note 1, the Company consummated the Business Combination, pursuant to the terms of the agreement and plan of merger, dated as of August 29, 2021 (the “Business Combination Agreement”), by and among Petra, Petra Acquisition Merger, Inc., a Delaware corporation and wholly -owned -owned In accordance with the terms and subject to the conditions of the Business Combination Agreement, at the effective time of the Merger (the “Effective Time”), (i) each share of common stock and preferred stock of Old Revelation outstanding as of immediately prior to the Effective Time was exchanged for shares of common stock, par value $0.001 per share, of Revelation based on the agreed upon Common Stock Exchange Ratio; (ii) each Old Revelation RSU award outstanding as of immediately prior to the Effective Time was assumed by Revelation and was converted into that number of whole rollover RSU awards based on the Common Stock Exchange Ratio (“Rollover RSU”); and (iii) each Old Revelation warrant outstanding as of immediately prior to the Effective Time was assumed by Revelation and was converted into that number of whole rollover warrants based on the Common Stock Exchange Ratio, at an exercise price per share of common stock equal to (x) the exercise price per share of Old Revelation common stock of such Old Revelation warrant divided by (y) the Common Stock Exchange Ratio (“Rollover Warrant”). At the Closing Date, up to 300,000 -1 Immediately after giving effect to the Business Combination, there were 369,836 -merger -Merger Prior to the Closing Date, on December 21, 2021, Petra entered into certain backstop agreements (the “Backstop Agreements”) with AXA Prime Impact Master Fund (“AXA”) (through a backstop agreement with Old Revelation), LifeSci Venture Partners (“LifeSci”) and other Petra and Old Revelation institutional, and individual investors, including Dr. Tidmarsh, Chairman of Old Revelation and present Chairman of the Company (such additional institutional and individual investors, together with LifeSci and Old Revelation collectively, the “Backstop Subscribers”). Pursuant to the Backstop Agreements, the Backstop Subscribers agreed to purchase, in the aggregate, up to $4.5 million of shares of Petra’s common stock, par value $0.001 per share, in the event that more than $31.5 million was redeemed from the trust account in connection with the Business Combination. On January 6, 2022, pursuant to the Backstop Agreements, the Backstop Subscribers purchased an aggregate of 12,345 On the Closing Date, in connection with the Business Combination, stockholders holding 99,449 At the closing of the Business Combination, Petra adopted the third amended and restated certificate of incorporation, which became effective upon filing with the Secretary of State of the State of Delaware on the Closing Date. Subsequent to the Closing Date on February 10, 2022 and February 22, 2022 the Company paid $105,490 and $691,392, respectively, to the three holders of promissory notes made to Petra in connection with the Business Combination (“Promissory Notes Payable”). The Promissory Notes Payable had a total principal of $750,000, and had accrued interest of $46,882 at the time of repayment. The Business Combination has been accounted for as a reverse recapitalization, in accordance with U.S. GAAP. Under this method of accounting, although Petra issued shares for outstanding equity interests of Old Revelation in the Business Combination, Petra was treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Old Revelation issuing stock for the net assets of Petra, accompanied by a recapitalization. The net assets of Petra have been stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of Revelation.

Balance Sheet Details

Balance Sheet Details	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Balance Sheet Details [Abstract]
Balance Sheet Details	3. Balance Sheet Details Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: September 30, 2023 December 31, 2022 Prepaid insurance costs $ 71,250 $ — Other prepaid expenses & current assets 81,387 73,132 Total prepaid expenses & current assets $ 152,637 $ 73,132 Property and Equipment, Net Property and equipment, net consisted of the following: September 30, 2023 December 31, 2022 Lab equipment $ 131,963 $ 131,963 Total property and equipment, gross 131,963 131,963 Accumulated depreciation (60,617 ) (41,830 ) Total property and equipment, net $ 71,346 $ 90,133 Depreciation expense was $6,262 and $18,787 for the three and nine months ended September 30, 2023, respectively, and $6,262 and $18,786 for the three and nine months ended September 30, 2022, respectively. Accrued Expenses Accrued expenses consisted of the following: September 30, 2023 December 31, 2022 Accrued payroll and related expenses $ 507,579 $ 618,014 Accrued clinical study expenses 31,661 175,061 Accrued professional fees 223,358 75,722 Accrued clinical development costs 259,437 111,700 Accrued other expenses — 5,000 Total accrued expenses $ 1,022,035 $ 985,497 Included in accrued other expenses as of December 31, 2022, was the $5,000 redemption price of the Series A Preferred Stock that automatically redeemed on January 30, 2023 upon the effectiveness of the Certificate of Amendment implementing the reverse stock split and an increase in the authorized shares of common stock of the Company (see Note 8).	4. Balance Sheet Details Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: December 31, December 31, Prepaid clinical costs $ — $ 488,614 Other prepaid expenses & current assets 73,132 148,728 Total prepaid expenses & current assets $ 73,132 $ 637,342 Property and Equipment, Net Property and equipment, net consisted of the following: December 31, December 31, Lab equipment $ 131,963 $ 131,963 Total property and equipment, gross 131,963 131,963 Accumulated depreciation (41,830 ) (16,782 ) Total property and equipment, net $ 90,133 $ 115,181 Depreciation expense was $25,048 for the year ended December 31, 2022 and $16,782 for the year ended December 31, 2021. Accrued Expenses Accrued expenses consisted of the following: December 31, December 31, Accrued payroll and related expenses $ 618,014 $ 756,729 Accrued clinical study expenses 175,061 327,244 Accrued professional fees 75,722 294,130 Accrued clinical development costs 111,700 145,566 Accrued other expenses 5,000 5,000 Total accrued expenses $ 985,497 $ 1,528,669 In connection with the Business Combination the Company entered into a payment deferral of legal fees with Loeb & Loeb, LLP, which, deferred the legal fees for six months from the Closing Date of the Business Combination, or July 9, 2022. The agreement stated, if the fees were not paid by July 9, 2022, 8,572 Included in accrued other expenses as of the year ended December 31, 2022, was the $5,000 redemption price of the Series A Preferred Stock that automatically redeemed on January 30, 2023 upon the effectiveness of the Certificate of Amendment implementing the reverse stock split and an increase in the authorized shares of common stock of the Company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	4. Commitments and Contingencies Lease Commitments In February 2021, Revelation Sub entered into an agreement to lease 2,140 square feet of laboratory space located at 11011 Torreyana Road, Suite 102, San Diego, California (the “Lease”). In January 2023, the Company signed an amendment extending the Lease until December 31, 2023, with a base monthly rent equal to $9,630. The Company is required to maintain a security deposit of $5,564. The Lease contains customary default provisions, representations, warranties and covenants. In addition to rent, the Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises. The Company has applied the short -term Rent expense was $28,890 and $82,771 for the three and nine months ended September 30, 2023, respectively, and $17,193 and $49,453 for the three and nine months ended September 30, 2022, respectively. Future minimum lease payments under the operating lease as of September 30, 2023 is $28,890. Convertible Note Financing On January 4, 2022, Revelation Sub entered into a convertible note with AXA Prime Impact Master Fund I SCA SICAV -RAIF On January 6, 2022, Old Revelation purchased 7,001 Total interest incurred under the Convertible Note was $0 and $14,383 during the three and nine months ended September 30, 2022, respectively. Commitments The Company enters into contracts in the normal course of business with third party service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation other than described below. Legal Proceedings On February 18, 2022, LifeSci Capital LLC filed an action against the Company in the U.S. District Court for the Southern District of New York seeking damages in the amount of approximately $2.7 million in cash and $2.6 million in equity for unpaid banking and advisory fees. These fees arise under contracts which were entered into prior to the Business Combination and the Company is disputing the amount owed under those contracts and has asserted affirmative defenses including the defense that LifeSci Capital LLC mislead Petra in the amount of funds that would be available for operation following the Business Combination. The Company has filed a counterclaim against LifeSci Capital LLC for damages arising from its misleading Petra. On June 22, 2022, LifeSci Capital LLC filed a motion for summary judgement and on March 2, 2023, the court denied the plaintiff’s motion for summary judgment. As of the date of this Report, discovery is substantially complete and LifeSci has filed a second motion for summary judgment which is pending. If the proceeding goes to trial it is not expected to occur, at the earliest, until the second half of 2024. Of the LifeSci Capital LLC claim, $1.5 million relates to deferred underwriting fees from the Petra initial public offering (“IPO”). In addition, but separate from the claim, one of the underwriters in the Petra IPO who is not a participant in the litigation with LifeSci Capital LLC recently issued a demand letter seeking repayment for $655 thousand in fees owed from the Petra initial public offering that remain unpaid. Both of these amounts are recorded as a current liability in the financial statements as of September 30, 2023 under deferred underwriting commissions. No other liabilities are reflected in the financial statements as the amount of any additional liability cannot be determined at this time. On September 27, 2022, A -IR -IR -IR	5. Commitments and Contingencies Lease Commitments In February 2021, Revelation Sub entered into an agreement to lease 2,140 square feet of laboratory space located at 11011 Torreyana Road, Suite 102, San Diego, California (the “Original Lease”). The Original Lease had a term of 13 calendar months, plus any partial month at the beginning of the Original Lease (the “Original Lease Term”). Revelation Sub recorded a lease liability and right -of-use In October 2021, Revelation Sub amended the Original Lease to expire on December 31, 2022, equal to an additional nine calendar months with a base monthly rent equal to the 13 th -term Rent expense was $66,645 for the year ended December 31, 2022 and $55,246 for the year ended December 31, 2021, respectively. There are no future minimum lease payments under the First Amendment of the operating lease as of December 31, 2022. Convertible Note Financing On January 4, 2022, Revelation Sub entered into a convertible note financing in an amount of up to $2.5 million with a fixed 10% annual interest rate from AXA IM Prime Impact Fund (the “Convertible Note”), the proceeds of which were used by Revelation Sub to purchase shares of Petra common stock from redeeming Petra stockholders who redeemed shares of Petra common stock in connection with the Business Combination. On January 6, 2022, Old Revelation purchased 7,001 Total interest incurred under the Convertible Note was $14,383 during the year ended December 31, 2022. Premium Finance Agreement — D&O Insurance In order to obtain a public company directors and officers insurance policy (“D&O Insurance”), the Company entered into an agreement with a premium financing lender, where by the lender paid the D&O Insurance premium for the company (“Premium Finance Agreement”). If the Company were to not pay the lender monthly installment payments, the lender would cancel the D&O Insurance and the remaining D&O Insurance premium would be returned to the lender. In addition, if the Company were to cancel the D&O Insurance, the remaining D&O Insurance premium would be returned to the lender. The Premium Finance Agreement is for $825,000 and accrues interest at a fixed rate of 3.57% per annum payable monthly for a total of $9,856 over the term of the Premium Finance Agreement. Monthly payments of $74,428, are to be paid in nine monthly installments, which commenced on February 10, 2022 with a maturity date of October 10, 2022. Upon entering into the Premium Finance Agreement, an upfront payment of $165,000 was due and paid on February 14, 2022. Total expense incurred under the Finance Agreement for upfront, monthly and interest payments was $834,856 during the year ended December 31, 2022. Total cash paid under the Finance Agreement for upfront, monthly and interest payments was $834,856 during the year ended December 31, 2022. There are no future obligations under the Premium Finance Agreement as of December 31, 2022. Commitments The Company enters into contracts in the normal course of business with third party service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation other than described below. Legal Proceedings On February 18, 2022, LifeSci Capital LLC filed an action against the Company in the U.S. District Court for the Southern District of New York seeking damages in the amount of approximately $2.7 million in cash and $2.6 million in equity for unpaid banking and advisory fees. These fees arise under contracts which were entered into prior to the Business Combination and the Company is disputing the amount owed under those contracts and has asserted affirmative defenses including the defense that the amount of the fees sought exceeded the $8.5 million cap on transaction expenses in the Business Combination Agreement. This action remains pending as of the date of this report. On March 2, 2023, the court denied the plaintiff’s motion for summary judgment. As of the date of this report, the court has not set any schedule for discovery or a timetable for any trial. Of the LifeSci Capital LLC claim, $1.5 million relates to deferred underwriting fees from the Petra initial public offering. In addition, but separate from the claim, one of the underwriters in the Petra initial public offering who is not a participant in the litigation with LifeSci Capital LLC recently issued a demand letter seeking repayment for $655 thousand in fees owed from the Petra initial public offering that remain unpaid. Both of these amounts are recorded as a current liability in the financial statements as of December 31, 2022 under deferred underwriting commissions. No other liabilities are reflected in the financial statements as the amount of any additional liability cannot be determined at this time. On September 27, 2022, A -IR -IR -IR On January 30, 2023, Marwood Advisory Group, LLC filed an action in the Supreme Court of New York for the County of New York seeking damages in the amount of $150,000 plus interest in respect of a contract agreed by the sponsors of Petra allegedly relating to a due diligence report with another target considered by Petra prior to the Business Combination. The Company believes it has defenses to this claim and as of the date of this report no answer is due. Since this proceeding is at a very early stage, no liability is reflected in the financial statements as the amount of any liability cannot be determined at this time.

PIPE Investment

PIPE Investment	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
PIPE Investment [Abstract]
PIPE Investment	5. PIPE Investment On January 25, 2022, the Company closed a private placement of 36,947 -funded -Funded -Funded Roth Capital Partners, LLC (“Roth”) was engaged by the Company to act as its exclusive placement agent for the private placement. The Company paid Roth a cash fee equal to 6.0% of the gross proceeds received by the Company in the private placement, totaling $465,600 and issued warrants to purchase up to 10,347 In connection with the private placement, the Company entered into a registration rights agreement with the institutional investor, pursuant to which the Company agreed to file a registration statement to register for resale of the shares of common stock, shares of common stock underlying the Class A Pre -Funded -1 -262410 On February 22, 2022, the Company received a notice of cash exercise for the total outstanding Class A Pre -Funded Using the Black -Scholes	6. PIPE Investment On January 23, 2022, the Company entered into a securities purchase agreement with an institutional investor (“the Purchaser”) pursuant to which the Purchaser agreed to purchase, and the Company agreed to issue and sell to the Purchaser in a private placement, 36,947 -funded -Funded Each Pre -Funded -Funded the Company’s outstanding common stock immediately after exercise. On February 22, 2022, the Company received a notice of cash exercise for the total outstanding Pre -Funded Each Class A Common Stock Warrant has an exercise price of $115.15 per share of common stock, is exercisable at any time after the sixth month anniversary of the date of issuance, will expire five and one -half Also on January 23, 2022 and in connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser, pursuant to which the Company agreed to use its best efforts to file a registration statement on Form S -1 -Funded Roth Capital Partners, LLC (the “Placement Agent”) was engaged by the Company to act as its exclusive placement agent for the private placement. The Company agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds received by the Company in the private placement, totaling approximately $465,600. In addition, the Company agreed to issue to the Placement Agent warrants to purchase up to 10,347 -Funded Using the Black -Scholes

Public Offering

Public Offering	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Public Offering [Abstract]
Public Offering	6. 2022 Public Offering On July 28, 2022, the Company closed a public offering of 238,096 Roth was engaged by the Company to act as its exclusive placement agent for the July 2022 Public Offering. The Company paid Roth a cash fee equal to 7.0% of the gross proceeds received by the Company in the public offering, totaling $350,000 and issued warrants to purchase up to 16,667 The shares of common stock, the shares of common stock underlying the Class B Common Stock Warrants and the shares of common stock underlying the Class B Placement Agent Common Stock Warrants were registered with the SEC on Form S -1 -266108 Using the Black -Scholes	7. Public Offering On July 28, 2022, the Company closed a public offering of 238,096 five -1 -266108 Roth Capital Partners, LLC (the “Placement Agent”) was engaged by the Company to act as its exclusive placement agent for the July 2022 Public Offering. The Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the gross proceeds received by the Company in the public offering, totaling $350,000. In addition, the Company agreed to issue to the Placement Agent warrants to purchase up to 16,667 five Using the Black -Scholes

Preferred Stock

Preferred Stock	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Preferred Stock [Abstract]
Preferred Stock	8. Preferred Stock Revelation Authorized Preferred Stock The Certificate of Amendment of the Company authorizes up to 5,000,000 -Q Series A Preferred Stock On December 19, 2022, the Company closed the sale of one share of the Company’s Series A Preferred Stock, par value $0.001 per share, to its Chief Executive Officer for $5,000.00. The outstanding share of Series A Preferred Stock was automatically redeemed for $5,000.00 on January 30, 2023 upon the effectiveness of the Certificate of Amendment implementing the reverse stock split and the increase in authorized shares of common stock of the Company. The Series A Preferred Stock had 50,000,000 votes and voted together with the outstanding shares of the Company’s common stock as a single class exclusively with respect to any proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock and to increase the number of authorized shares of common stock of the Company. The Series A Preferred Stock voted, without action by the holder, on any such proposal in the same proportion as shares of common stock voted. The Series A Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware.	8. Preferred Stock Revelation Authorized Preferred Stock The third amended and restated certificate of incorporation of the Company authorizes up to 5,000,000 Series A Preferred Stock On December 19, 2022, the Company entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with James Rolke, its Chief Executive Officer, who is an accredited investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell one (1) share of the Company’s Series A Preferred Stock, par value $0.001 per share, to the Purchaser for $5,000.00 in cash. The sale closed on December 19, 2022. The Series A Preferred Stock had 50,000,000 votes and voted together with the outstanding shares of the Company’s common stock as a single class exclusively with respect to any proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock and to increase the number of authorized shares of common stock of the Company. The Series A Preferred Stock voted, without action by the holder, on any such proposal in the same proportion as shares of common stock voted. The Series A Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. The Series A Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series A Preferred Stock had no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series A Preferred Stock was not entitled to receive dividends of any kind. The outstanding share of Series A Preferred Stock was automatically redeemed on January 30, 2023 upon the effectiveness of the Certificate of Amendment implementing the reverse stock split and the increase in authorized shares of common stock of the Company. Upon such redemption, the holder of the Series A Preferred Stock received the redemption price of $5,000.00 in cash. Revelation Sub Authorized Preferred Stock Prior to the Merger, in August 2020, Revelation Sub authorized the sale and issuance of up to 2,000,000 -1 Revelation Sub Series A Preferred Stock Prior to the Merger, in December 2020, Revelation Sub sold and issued 628,930 Revelation Sub Series A-1 Preferred Stock Prior to the Merger, in January 2021, Revelation Sub sold and issued 684,450 -1 -1

Units

Units	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Units [Abstract]
Units	9. Units In connection with Petra’s IPO, in October of 2020, Petra issued unit’s that consisted of one share of common stock and one warrant exercisable for 1/35 of a share of common stock with an exercise price of $402.50 per share which expire on January 10, 2027 (the “Public Warrants”), which traded on the Nasdaq Capital Market under the ticker symbol REVBU. As disclosed in Note 1, on January 13, 2023, the Company’s units were mandatorily separated, ceased to exist and stopped trading on the Nasdaq Capital Market. At the time of separation there were 1,688,598 units separated, which represented 48,246 No	9. Units In connection with the Petra’s IPO, in October of 2020, Petra issued unit’s that consisted of one share of common stock and one warrant with an exercise price of $402.50 per shares (the “Public Warrants”). As of December 31, 2022 there were 48,246 units outstanding (not effected for the reverse split), which trade on the Nasdaq Capital Market under the ticker symbol “REVBU.” The Company includes each share of common stock and Public Warrant from the unit’s in its calculation of common stock and Public Warrants outstanding, respectively.

Common Stock

Common Stock	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Common Stock [Abstract]
Common Stock	10. Common Stock The Company is authorized under its articles of incorporation, as amended, to issue 500,000,000 Reverse Split As disclosed in Note 1, on January 30, 2023, the Company filed the Certificate of Amendment reflecting the change in authorized shares of common stock from 100,000,000 to 500,000,000 and effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on February 1, 2023 with a ratio of 1 -for-35 -outstanding Common Stock Issuance due to the Business Combination On the Closing Date, the Company issued an aggregate of 282,039 Common Stock Issuance during the year ended December 31, 2022 On January 23, 2022, the Company issued 36,947 On January 31, 2022, the Company issued 8,572 On February 2, 2022, the Company issued 54 On February 4, 2022, the Company cancelled 21,429 On February 22, 2022, the Company issued 36,959 -Funded On July 28, 2022, the Company issued 238,096 On July 29, 2022, the Company issued 3,435 Common Stock Issuance during the three and nine months ended September 30, 2023 On February 13, 2023, the Company issued 2,888,600 On February 14, 2023, the Company issued 33,000 -Funded On March 2, 2023, the Company issued 160,000 -Funded From March 13, 2023 to March 31, 2023, the Company issued 965,357 From April 1, 2023 to June 30, 2023, the Company issued 1,419,780 On April 6, 2023, the Company received a notice of cash exercise for the Class C Pre -Funded On April 18, 2023, the Company issued 4,284 As of September 30, 2023 and December 31, 2022, 6,297,303 and 682,882 The total shares of common stock reserved for issuance are summarized as follows: September 30, 2023 September 30, 2022 Public Warrants (exercise price of $402.50 per share) 300,332 300,332 Class A Common Stock Warrants (exercise price of $115.15 per share) 73,905 73,905 Class A Placement Agent Common Stock Warrants (exercise price of $115.15 per share) 10,347 10,347 Class B Common Stock Warrants (exercise price of $21.00 per share) 238,095 238,095 Class B Placement Agent Common Stock Warrants (exercise price of $26.25 per share) 16,667 16,667 Class C Common Stock Warrants (exercise price of $5.36 per share) 487,160 — Rollover Warrants (exercise price of $93.80 per share) 4,738 4,738 Rollover RSU awards outstanding 3,006 7,290 Stock options outstanding 35,005 10,058 Shares reserved for issuance 1,169,255 661,432 Shares available for future stock grants under the 2021 Equity Incentive Plan 33,283 58,230 Total common stock reserved for issuance 1,202,538 719,662	10. Common Stock The Company is authorized under its articles of incorporation, as amended, to issue 500,000,000 Reverse Split On January 30, 2023, the Company filed the Certificate of Amendment reflecting the change in authorized shares of common stock from 100,000,000 to 500,000,000 and effecting a reverse stock split as of 12:01 a.m. Eastern Standard Time on February 1, 2023 with a ratio of 1 -for-35 -outstanding Common Stock Issuance due to the Business Combination At the Closing Date, the Company issued an aggregate of 282,039 On the Closing Date, the Company received net proceeds from the Business Combination of $11.9 million, of which $7.7 million was escrowed pursuant to a Forward Share Purchase Agreement entered into by Petra and $4.2 million was released to Revelation. Common Stock Issuance during the year ended December 31, 2022 On January 23, 2022, the Company issued 36,947 On January 31, 2022, the Company issued 8,572 On February 4, 2022, the Company cancelled 21,429 On February 22, 2022, the Company issued 36,959 -Funded On February 2, 2022, the Company issued 54 On July 28, 2022, the Company issued 238,096 On July 29, 2022, the Company issued 3,435 As of December 31, 2022 and December 31, 2021, 682,882 and 282,039 The total shares of common stock reserved for issuance are summarized as follows: December 31, December 31, Revelation Sub Series A Preferred Stock — — Series A-1 Preferred Stock — — Public Warrants 300,332 — Class A Common Stock Warrants 73,905 — Class A Placement Agent Common Stock Warrants 10,347 — Class B Common Stock Warrants 238,096 — Class B Placement Agent Common Stock Warrants 16,667 — Rollover Warrants 4,738 4,792 Unvested and unissued Rollover RSU awards 7,290 13,154 Stock options outstanding 9,581 — Shares reserved for issuance 660,956 17,946 Shares available for future stock grants under the 2021 Equity Incentive Plan 58,707 — Total common stock reserved for issuance 719,663 17,946

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation 2021 Equity Incentive Plan In January 2022, in connection with the Business Combination, the Board of Directors and the Company’s stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 36,983 authorized shares of common stock for issuance under the plan. The 2021 Plan is administered by the Board of Directors. Vesting periods and other restrictions for grants under the 2021 Plan are determined at the discretion of the Board of Directors. Grants to employees, officers, directors, advisors, and consultants of the Company typically vest over one to four years. In addition, the number of shares of stock available for issuance under the 2021 Plan will be automatically increased each January 1, and began on January 1, 2022, by 10% of the aggregate number of outstanding shares of our common stock from the first day of the preceding calendar year to the first day of the current calendar year or such lesser number as determined by our board of directors. On January 1, 2023, after effecting the Reverse Split the total shares available for issuance under the 2021 Equity Plan was increased to 68,288 authorized shares of common stock. Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five As of September 30, 2023, there were 33,283 shares available for future grant under the 2021 Plan. Restricted Stock Units At the Closing Date of the Business Combination, all Revelation Sub RSU award holders received a Rollover RSU award in exchange for each RSU award of Revelation Sub that vest in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock -based The Rollover RSU awards have time -based -based -based -based As of September 30, 2023 and December 31, 2022, the Company has a total of 3,006 and 7,290 Rollover RSU awards for shares of common stock outstanding, respectively. As of September 30, 2023, 1,371 Rollover RSU awards have fully vested but are unissued and no Rollover RSU awards have been forfeited. As of September 30, 2023, 1,635 Rollover RSU awards will vest and be issued over the next 1.4 years. Each Rollover RSU award converts to one share of common stock. Stock Options The Company has granted stock options which (i) vest fully on the date of grant; (ii) vest 25% on the one year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter; or (iii) vest quarterly over one year, for grants to Board of Directors, officers and employees. Stock options have a maximum term of 3 or 10 years. The activity related to stock options, during the nine months ended September 30, 2023 is summarized as follows: Shares Weighted- average Exercise Price Weighted- average Remaining Contractual Term (Years) Outstanding at December 31, 2022 9,581 $ 31.91 Granted 25,424 1.19 Exercised — — Expired and forfeited — — Outstanding at September 30, 2023 35,005 $ 9.60 8.2 Exercisable at September 30, 2023 32,514 $ 6.58 8.2 For the nine months ended September 30, 2023, the weighted -average -Scholes -Scholes -average Volatility 126.0 % Expected term (years) 5.03 Risk-free interest rate 3.09 % Expected dividend yield 0.0 % Expected volatility is based on the historical volatility of shares of the Company’s common stock. In determining the expected term of stock options, the Company uses the “simplified” method. Under this method, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. The risk -free -Scholes -based Stock-Based Compensation Expense For the three and nine months ended September 30, 2023 and 2022, the Company recorded stock -based Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 General and administrative: RSU awards $ 22,384 $ 23,928 $ 67,150 $ 108,040 Stock Options 7,216 (10,912 ) 48,988 36,784 General and administrative stock-based compensation expense 29,600 13,016 116,138 144,824 Research and development: RSU awards 1,898 6,021 5,694 39,608 Stock Options 598 21,638 1,794 84,323 Research and development stock-based compensation expense 2,496 27,659 7,488 123,931 Total stock-based compensation expense $ 32,096 $ 40,675 $ 123,626 $ 268,755 As of September 30, 2023, there was $131,185 and $75,191 of unrecognized stock -based -based	11. Stock-Based Compensation 2020 Equity Incentive Plan and 2021 Equity Incentive Plan Prior to the Merger, Revelation Sub adopted the Revelation Biosciences, Inc. 2020 Equity Incentive Plan (the “2020 Plan”) on October 1, 2020 for the issuance of stock -based In January 2022, in connection with the Business Combination, the Board of Directors adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 36,983 authorized shares of common stock the Company could issue. The 2021 Plan is administered by the Board of Directors. Vesting periods and other restrictions for grants under the 2021 Plan are determined at the discretion of the Board of Directors. Grants to employees, officers, directors, advisors, and consultants of the Company typically vest over one to four years. In addition, the number of shares of stock available for issuance under the 2021 Plan will be automatically increased each January 1, beginning on January 1, 2022, by 10% of the aggregate number of outstanding shares of our common stock from the first day of the preceding calendar year to the first day of the current calendar year or such lesser number as determined by our board of directors. On January 1, 2023, after effecting the Reverse Split the total shares available for issuance under the 2021 Equity Plan was increased to 68,288 authorized shares of common stock. Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five As of December 31, 2022, there were 58,707 Restricted Stock Units At the Closing Date of the Business Combination, all Revelation Sub RSU award holders received a Rollover RSU award in exchange for each RSU award of Revelation Sub that vest in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock -based The Rollover RSU awards have time -based -based -based -based As of December 31, 2022 and December 31, 2021, the Company has a total of 7,290 and 13,154 Rollover RSU awards for shares of common stock outstanding, respectively. During the year ended December 31, 2022, 3,435 Rollover RSU awards have fully vested and been issued and 2,429 Rollover RSU awards have been forfeited. As of December 31, 2022, 7,290 Rollover RSU awards will vest and be issued over the next 2.4 years. Each Rollover RSU award converts to one share of common stock. Stock Options The Company has granted stock options which vest 25% on the one year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter for grants to officers and employees. Stock options have a maximum term of 10 years. On July 29, 2022, in connection with the release of 9 employees, the Board of Directors granted 5,590 stock options for shares of common stock that vest 100% on the date of grant. The stock options have a maximum term of 3 years. The activity related to stock options, during the year ended December 31, 2022 is summarized as follows: Shares Weighted- Weighted- Outstanding at December 31, 2021 — $ — Granted 15,708 38.57 Exercised — — Expired and forfeited (6,127 ) 49.00 Outstanding at December 31, 2022 9,581 $ 31.91 3.5 Exercisable at December 31, 2022 5,590 $ 19.71 2.6 For the year ended December 31, 2022, the weighted -average -Scholes -Scholes -average Volatility 96.5 % Expected term (years) 5.00 Risk-free interest rate 2.27 % Expected dividend yield 0.0 % Expected volatility is based on the historical volatility of shares of the Company’s common stock. In determining the expected term of stock options, the Company uses the “simplified” method. Under this method, the expected term is presumed to be the midpoint between the average vesting date and the end of the contractual term. The risk -free -Scholes -based Stock-Based Compensation Expense For the years ended December 31, 2022 and 2021, the Company recorded stock -based Year Ended 2022 2021 General and administrative: RSU awards $ 130,689 $ 412,214 Stock Options 44,000 — General and administrative stock-based compensation expense 174,689 412,214 Research and development: RSU awards 41,506 58,664 Stock Options 84,921 — Research and development stock-based compensation expense 126,427 58,664 Total stock-based compensation expense $ 301,116 $ 470,878 As of December 31, 2022, there was $204,030 and $98,633 of unrecognized stock -based -based

Warrants

Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Warrants [Abstract]
Warrants	12. Warrants Public Warrants In connection with Petra’s IPO, Petra issued 10,511,597 Public Warrants to purchase an aggregate of 300,332 The Company may redeem the Public Warrants at a price of $0.01 per Public Warrant upon not less than 30 days’ prior written notice of redemption if, and only if, the reported last sale price of the Company’s common stock equals or exceeds $630.00 per share for any 20 trading days within a 30 -trading Rollover Warrants Prior to the Merger, Revelation Sub issued warrants to a placement agent to purchase up to 4,792 shares of common stock with an exercise price of $93.80 per share which expire on January 31, 2027, valued on the issuance date in the aggregate at $326,675. At the Closing Date of the Business Combination, all warrant holders received a Rollover Warrant, which was exercisable in accordance with its original issuance. On February 2, 2022, the Company received a notice of cash exercise for the Company’s Rollover Warrants for 54 The fair value of the Rollover Warrants were estimated using the Black -Scholes Volatility 115 % Expected term (years) 6 Risk-free interest rate 0.85 % Expected dividend yield 0.0 % Class A Pre-Funded Warrants In connection with the PIPE Investment, the Company issued pre -funded On February 22, 2022, the Company received a notice of cash exercise for the Class A Pre -Funded -Funded Class A Common Stock Warrants In connection with the PIPE Investment, the Company issued warrants to an institutional investor to purchase up to 73,905 The fair value of the Class A Common Stock Warrants were estimated using the Black -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % Class A Placement Agent Common Stock Warrants In connection with the PIPE Investment, the Company issued warrants to Roth to purchase an aggregate of 10,347 The fair value of the Class A Placement Agent Common Stock Warrants were estimated using the Black -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % Class B Common Stock Warrants In connection with the July 2022 Public Offering, the Company issued 8,333,334 warrants to purchase an aggregate of 238,095 shares of common stock at an exercise price of $21.00 per share, valued on the public offering purchase date in the aggregate at $4.5 million and included in the issuance costs of the public offering. The warrants were exercisable immediately upon issuance, provide for a cash or cashless exercise right and expire on July 28, 2027. The fair value of the Class B Common Stock Warrants were estimated using the Black -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 % Class B Placement Agent Common Stock Warrants In connection with the July 2022 Public Offering, the Company issued warrants to the Placement Agent to purchase up to 16,667 The fair value of the Class B Placement Agent Common Stock Warrants were estimated using the Black -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 % Class C Pre-Funded Warrants In connection with the February 2023 Public Offering, the Company issued pre -funded -Funded -Funded Class C Common Stock Warrants In connection with the February 2023 Public Offering, the Company issued warrants to purchase up to 6,450,000 The Company accounted for the Class C Common Stock Warrants as current liabilities based upon the guidance of ASC 480 and ASC 815. The Company evaluated the Class C Common Stock Warrants under ASC 815 -40 -40 The Company concluded that the multiplier of 0.4 -classified -based and sensitive to changes in the trading market price of the Company’s common stock. Because liability -classified At the date of issuance, the Company valued the Class C Common Stock Warrants using a Monte -Carlo As of September 30, 2023, the Company received notices of alternative cashless exercises for 5,962,840 Class C Common Stock Warrants issued in connection with the February 2023 Public Offering for 2,385,137 shares of common stock. As of September 30, 2023, the Company re -valued -Carlo	12. Warrants Public Warrants In connection with the Petra’s IPO, Petra issued 10,511,597 Public Warrants to purchase an aggregate of 300,332 The Company may redeem the Public Warrants at a price of $0.01 per Public Warrant upon not less than 30 days’ prior written notice of redemption if, and only if, the reported last sale price of the Company’s common stock equals or exceeds $630.00 per share for any 20 trading days within a 30 -trading Rollover Warrants Prior to the Merger, in connection with the issuance of the Revelation Sub Series A -1 -1 Preferred Stock in the aggregate at $326,675 and included in the issuance costs of the Revelation Sub Series A -1 At the Closing Date of the Business Combination, all warrant holders received a Rollover Warrant, which was exercisable in accordance with its original issuance. On February 2, 2022, the Company received a notice of cash exercise for the Company’s Rollover Warrants for 54 The fair value of the Rollover Warrants was estimated using the Black -Scholes Volatility 115 % Expected term (years) 6 Risk-free interest rate 0.85 % Expected dividend yield 0.0 % Class A Common Stock Warrants In connection with the PIPE Investment, the Company issued warrants to the Purchaser to purchase an aggregate of 73,905 The fair value of the warrants was estimated using the Black -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % Pre-Funded Warrants In connection with the PIPE Investment, the Company issued warrants to the Purchaser to purchase an aggregate of 36,959 On February 22, 2022, the Company received a notice of cash exercise for the Pre -Funded Class A Placement Agent Common Stock Warrants In connection with the PIPE Investment, the Company issued warrants to the Placement Agent to purchase an aggregate of 10,347 The fair value of the warrants was estimated using the Black -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % Class B Common Stock Warrants In connection with the July 2022 Public Offering, the Company issued 8,333,334 warrants to purchase an aggregate of 238,095 The fair value of the warrants was estimated using the Black -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 % Class B Placement Agent Common Stock Warrants In connection with the July 2022 Public Offering, the Company issued warrants to the Placement Agent to purchase an aggregate of 16,667 The fair value of the warrants was estimated using the Black -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 %

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Income Taxes [Abstract]
Income Taxes	13. Income Taxes The quarterly provision for or benefit from income taxes is computed based upon the estimated annual effective tax rate and the year -to-date -tax not For the three and nine months ended September 30, 2023, the Company recorded non -taxable	13. Income Taxes The Company did not record a provision for income taxes for the years ended December 31, 2022 and December 31, 2021 due to a full valuation allowance against its deferred tax assets. The difference between the provision for income taxes and income taxes computed using the effective U.S. federal statutory rate is as follows: Year Ended 2022 2021 Federal tax statutory rate 21.0 % 21.0 % State tax, net of federal benefit 7.2 7.1 Research and development credits 0.6 1.9 Non-deductible expenses 2.9 (2.3 ) Change in valuation allowance (31.7 ) (27.7 ) Effective tax rate — % — % Significant components of the Company’s deferred tax assets are as follows: Year Ended 2022 2021 Net operating loss carryforwards $ 5,511,086 $ 3,524,526 Research and development credits 324,661 255,656 Capitalized research and development costs 1,429,419 — Capitalized start-up costs 860,853 — Other, net 373,936 351,836 Total gross deferred tax assets 8,499,983 4,132,018 Valuation allowance (8,499,983 ) (4,132,018 ) Net deferred tax assets $ — $ — As of December 31, 2022 and 2021, a full valuation allowance of $8,499,983 and $4,132,018, respectively, was established against its deferred tax assets due to the uncertainty surrounding the realization of such assets. The valuation allowance increased by $4,012,802 and $3,323,197 in 2022 and 2021, respectively, due to the increase in the deferred tax assets by the same amount; primarily due to net operating loss carryforwards and the mandatory capitalization of qualified research and development expenses in 2022. As of December 31, 2022, the Company had federal and state net operating loss carryforwards of $18,224,037 and $24,505,008, respectively. As of December 31, 2021, the Company had federal and state net operating loss carryforwards of $12,468,027 and $13,221,253, respectively. Federal net operating losses carryforward indefinitely. State net operating loss carryforwards will begin to expire in 2026 The Company had estimated federal research and development credit carryforwards of $93,915 and $91,217 as of December 31, 2022 and 2021, respectively. The federal research tax credit carryforwards will begin to expire in 2040 Pursuant to Section 382 and 383 of the Internal Revenue Code (“IRC”), utilization of the Company’s federal net operating loss carryforwards and research and development credit carryforwards may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating loss and research and development credit carryforwards prior to utilization. The Company has not completed an IRC Section 382 and 383 analyses regarding the limitation of net operating loss and research and development credit carryforwards. No liability is recorded on the financial statements related to uncertain tax positions. There are no The Company’s policy is to record estimated interest and penalties related to uncertain tax benefits as income tax expense. As of December 31, 2022 and 2021, the Company had no The Company is subject to taxation in the U.S. and various state jurisdictions. The Company’s tax returns since inception are subject to examination by the U.S. and various state tax authorities. The Company is not currently undergoing a tax audit in any federal or state jurisdiction. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act. The tax relief measures for businesses in the CARES Act include a five -year -tax The Consolidated Appropriation Act (“CAA”) of 2021 was signed into law by the President, December 27, 2020, containing the most recent COVID -19

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events In preparing these condensed consolidated financial statements, the Company has evaluated and determined there are no events and transactions for potential recognition or disclosure through November 9, 2023, the date the financial statements were available to be issued.	14. Subsequent Events Unit Separation On January 13, 2023, the Company’s units, which traded with the ticker symbol “REVBU” were mandatorily separated and cease to exist, further the units no longer trade on the Nasdaq Capital Market. Each unit was comprised of one share of the Company’s common stock and one Public Warrant. At the time of separation there were 1,688,598 units separated, no Second Amendment to Lease In January 2023, Revelation Sub amended the First Amendment to the Original Lease (the “Second Amendment”) to expire on December 31, 2023, equal to an additional 11 calendar months with a base monthly rent equal to $9,630.00. Revelation Sub signed the Second Amendment on January 17, 2023. The Company will pay $105,930 of rent expense over the life of the Second Amendment. Change in Authorized Shares and Reverse Stock Split On January 30, 2023, at a special meeting of stockholders, the Company’s stockholders approved a Certificate of Amendment to the Company’s Third Amended and Restated Certificate of Incorporation to change the authorized common stock from 100,000,000 to 500,000,000 -for-twenty -for-20 -for-one -for-100 -for-35 Public Offering On February 13, 2023, the Company closed a public offering of (i) an aggregate of 2,888,600 -funded -Funded -Funded -Funded five -300 -100 -200 -99b -1 -268576 Roth Capital Partners, LLC (the “Placement Agent’) was engaged by the Company to act as its exclusive placement agent for the public offering. The Company agreed to pay the Placement Agent a cash fee equal to 8.0% of the gross proceeds received by the Company in the public offering, totaling approximately $1.2 million. Using the Black -Scholes As a result of the proceeds from the Public Offering, the Company believes it is now in compliance with Listing Rule 5550(b)(2) because it has stockholders’ equity in excess of $2.5 million as of the date of this filing. Regaining NASDAQ Compliance On February 16, 2023, the Company received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company’s common stock will continue to be listed and traded on Nasdaq, due to the Company having regained compliance with the minimum bid price requirement and minimum stockholders’ equity requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1), respectively, and all applicable listing standards. As previously reported in 2022, Nasdaq issued delist letters based on the Company’s non -compliance Also, as previously reported on February 13, 2023, the Company closed a Public Offering on February 13, 2023, resulting in estimated net cash proceeds of approximately $14.0 million after accounting for estimated expenses incurred in connection with the Public Offering. As a result, the Listing Qualifications staff determined that the Company has regained compliance with the minimum equity requirement. The staff also determined as of February 15, 2023, the Company has evidenced compliance with the $1.00 per share price requirement having traded for 11 consecutive trading days above $1.00. Pre-Funded Warrant Exercise On February 14, 2023, the Company received a notice of cash exercise for the Pre -Funded On March 2, 2023, the Company received a notice of cash exercise for the Pre -Funded Class C Common Stock Warrant Exercise As of March 20, 2023, the Company received notices of alternative cash -less

2023 Public Offering

2023 Public Offering	9 Months Ended
	Sep. 30, 2023
2023 Public Offering [Abstract]
2023 Public Offering	7. 2023 Public Offering On February 13, 2023, the Company closed a public offering of 2,888,600 -funded -Funded -Funded Roth was engaged by the Company to act as its exclusive placement agent for the February 2023 Public Offering. The Company paid Roth a cash fee equal to 8.0% of the gross proceeds received by the Company in the public offering, totaling $1.2 million. The shares of common stock, the shares of common stock underlying the Class C Pre -Funded -1 -268576 Between February 14, 2023 and April 6, 2023, the Company received notices of cash exercise for the Class C Pre -Funded no -Funded Using a Monte -Carlo From March 13, 2023 to September 30, 2023, the Company issued 2,385,137

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s condensed consolidated financial statements.	Use of Estimates The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. These estimates and assumptions are based on the Company’s best estimates and judgment. The Company regularly evaluates its estimates and assumptions using historical and industry experience and other factors; however, actual results could differ materially from these estimates and could have an adverse effect on the Company’s consolidated financial statements.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. The Company maintains its cash in checking and savings accounts. Income generated from cash held in savings accounts is recorded as interest income. The carrying value of the Company’s savings accounts is included in cash and approximates the fair value.	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. The Company maintains its cash in checking and savings accounts. Income generated from cash held in savings accounts is recorded as interest income. The carrying value of the Company’s savings accounts is included in cash and approximates the fair value.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents.	Concentrations of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of federally insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third -party -process	Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third -party -process
Property and Equipment, Net	Property and Equipment, Net Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight -line five	Property and Equipment, Net Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight -line five
Leases	Leases The Company determines if an arrangement is a lease at inception. Lease right -of-use -of-use -of-use -line	Leases The Company determines if an arrangement is a lease at inception. Lease right -of-use -of-use -of-use -line
Research and Development Expenses	Research and Development Expenses Research and development expenses consist primarily of costs incurred for the development of the Company’s product candidates, REVTx -300 -100 -200 -99a -501	Research and Development Expenses Research and development expenses consist primarily of costs incurred for the development of the Company’s product candidates, REVTx -300 -100 -200 -99a -501
Patent Costs	Patent Costs Legal costs in connection with approved patents and patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are recorded in general and administrative expense in the condensed consolidated statements of operations.	Patent Costs Legal costs in connection with approved patents and patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are recorded in general and administrative expense in the statements of operations.
Stock-based Compensation	Stock-based Compensation The Company recognizes compensation expense related to stock options, third -party -based -party -Scholes -pricing -free dividends. The grant date fair value of the stock -based -line -based -based	Stock-based Compensation The Company recognizes compensation expense related to stock options, third -party -based -party -Scholes -pricing -free dividends. The grant date fair value of the stock -based -line -based -based
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or loss in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Interest and penalties related to unrecognized tax benefits are included within the provision of income tax. To date, there have been no unrecognized tax benefits balances.	Income Taxes Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or loss in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Interest and penalties related to unrecognized tax benefits are included within the provision of income tax. To date, there have been no
Basic and Diluted Net (Loss) Earnings per Share	Basic and Diluted Net (Loss) Earnings per Share Basic net (loss) earnings per share is calculated by dividing net (loss) income by the weighted -average -average -dilutive For the three months ended September 30, 2023, there were 1,169,255 potential shares of common stock, (see Note 10), that were excluded from the calculation of diluted net loss per share because their effect was anti -dilutive -dilutive The basic and diluted weighted -average	Basic and Diluted Net Loss per Share Basic net loss per share is calculated by dividing net loss by the weighted -average -average -dilutive -dilutive -average
Comprehensive (Loss) Income	Comprehensive (Loss) Income The Company has no components of comprehensive (loss) income other than net (loss) income. Thus, comprehensive (loss) income is the same as net (loss) income for the periods presented.	Comprehensive Loss The Company has no components of comprehensive loss other than net loss. Thus, comprehensive loss is the same as net loss for the periods presented.
Segment Reporting	Segment Reporting Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations for the purposes of allocating resources and evaluating financial performance.	Segment Reporting Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision -making The Company has one operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations for the purposes of allocating resources and evaluating financial performance.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. The Company has evaluated recently issued accounting pronouncements and does not believe any will have a material impact on the Company’s condensed consolidated financial statements or related financial statement disclosures.	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019 -12 Simplifying the Accounting for Income Taxes (Topic 740) (“ASU 2019 -12 ”). -12 -period interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. This guidance is effective for fiscal years beginning after December 15, 2021, and interim periods within the fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company’s adoption of the ASU 2019 -12
Unaudited Interim Condensed Consolidated Financial Statements	Unaudited Interim Condensed Consolidated Financial Statements The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements as of December 31, 2022 and for the year ended December 31, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine months ended September 30, 2023 are unaudited. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other future annual or interim period. The condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included on Form 10 -K -K
Fair Value	Fair Value Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company follows a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. These levels of inputs are the following: • • • The Company has determined that the measurement of the fair value of the Class C Common Stock Warrants (as defined in Note 7) is a Level 3 fair value measurement and uses the Monte -Carlo
Warrant Liability	Warrant Liability The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants. The Company accounts for its common stock warrants in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). Based upon the provisions of ASC 480 and ASC 815, the Company accounts for common stock warrants as current liabilities if the warrant fails the equity classification criteria. Common stock warrants classified as liabilities are initially recorded at fair value on the grant date and remeasured at each balance sheet date with the offsetting adjustments recorded in change in fair value of warrant liabilities within the condensed consolidated statements of operations. The Company values its common stock warrants classified as liabilities using either the Black -Scholes -Carlo

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Balance Sheet Details [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: September 30, 2023 December 31, 2022 Prepaid insurance costs $ 71,250 $ — Other prepaid expenses & current assets 81,387 73,132 Total prepaid expenses & current assets $ 152,637 $ 73,132	Prepaid expenses and other current assets consisted of the following: December 31, December 31, Prepaid clinical costs $ — $ 488,614 Other prepaid expenses & current assets 73,132 148,728 Total prepaid expenses & current assets $ 73,132 $ 637,342
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: September 30, 2023 December 31, 2022 Lab equipment $ 131,963 $ 131,963 Total property and equipment, gross 131,963 131,963 Accumulated depreciation (60,617 ) (41,830 ) Total property and equipment, net $ 71,346 $ 90,133	Property and equipment, net consisted of the following: December 31, December 31, Lab equipment $ 131,963 $ 131,963 Total property and equipment, gross 131,963 131,963 Accumulated depreciation (41,830 ) (16,782 ) Total property and equipment, net $ 90,133 $ 115,181
Schedule of Accrued Expenses	Accrued expenses consisted of the following: September 30, 2023 December 31, 2022 Accrued payroll and related expenses $ 507,579 $ 618,014 Accrued clinical study expenses 31,661 175,061 Accrued professional fees 223,358 75,722 Accrued clinical development costs 259,437 111,700 Accrued other expenses — 5,000 Total accrued expenses $ 1,022,035 $ 985,497	Accrued expenses consisted of the following: December 31, December 31, Accrued payroll and related expenses $ 618,014 $ 756,729 Accrued clinical study expenses 175,061 327,244 Accrued professional fees 75,722 294,130 Accrued clinical development costs 111,700 145,566 Accrued other expenses 5,000 5,000 Total accrued expenses $ 985,497 $ 1,528,669

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Common Stock [Abstract]
Schedule of Total Shares of Common Stock Reserved for Issuance	The total shares of common stock reserved for issuance are summarized as follows: September 30, 2023 September 30, 2022 Public Warrants (exercise price of $402.50 per share) 300,332 300,332 Class A Common Stock Warrants (exercise price of $115.15 per share) 73,905 73,905 Class A Placement Agent Common Stock Warrants (exercise price of $115.15 per share) 10,347 10,347 Class B Common Stock Warrants (exercise price of $21.00 per share) 238,095 238,095 Class B Placement Agent Common Stock Warrants (exercise price of $26.25 per share) 16,667 16,667 Class C Common Stock Warrants (exercise price of $5.36 per share) 487,160 — Rollover Warrants (exercise price of $93.80 per share) 4,738 4,738 Rollover RSU awards outstanding 3,006 7,290 Stock options outstanding 35,005 10,058 Shares reserved for issuance 1,169,255 661,432 Shares available for future stock grants under the 2021 Equity Incentive Plan 33,283 58,230 Total common stock reserved for issuance 1,202,538 719,662	The total shares of common stock reserved for issuance are summarized as follows: December 31, December 31, Revelation Sub Series A Preferred Stock — — Series A-1 Preferred Stock — — Public Warrants 300,332 — Class A Common Stock Warrants 73,905 — Class A Placement Agent Common Stock Warrants 10,347 — Class B Common Stock Warrants 238,096 — Class B Placement Agent Common Stock Warrants 16,667 — Rollover Warrants 4,738 4,792 Unvested and unissued Rollover RSU awards 7,290 13,154 Stock options outstanding 9,581 — Shares reserved for issuance 660,956 17,946 Shares available for future stock grants under the 2021 Equity Incentive Plan 58,707 — Total common stock reserved for issuance 719,663 17,946

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Options Activity	The activity related to stock options, during the nine months ended September 30, 2023 is summarized as follows: Shares Weighted- average Exercise Price Weighted- average Remaining Contractual Term (Years) Outstanding at December 31, 2022 9,581 $ 31.91 Granted 25,424 1.19 Exercised — — Expired and forfeited — — Outstanding at September 30, 2023 35,005 $ 9.60 8.2 Exercisable at September 30, 2023 32,514 $ 6.58 8.2	The activity related to stock options, during the year ended December 31, 2022 is summarized as follows: Shares Weighted- Weighted- Outstanding at December 31, 2021 — $ — Granted 15,708 38.57 Exercised — — Expired and forfeited (6,127 ) 49.00 Outstanding at December 31, 2022 9,581 $ 31.91 3.5 Exercisable at December 31, 2022 5,590 $ 19.71 2.6
Schedule of Assumptions used in Estimating Fair Value of Stock Options	The fair value of the stock options was estimated using the Black -Scholes -average Volatility 126.0 % Expected term (years) 5.03 Risk-free interest rate 3.09 % Expected dividend yield 0.0 %	The fair value of the stock options was estimated using the Black -Scholes -average Volatility 96.5 % Expected term (years) 5.00 Risk-free interest rate 2.27 % Expected dividend yield 0.0 %
Schedule of Stock-Based Compensation Expense	For the three and nine months ended September 30, 2023 and 2022, the Company recorded stock -based Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 General and administrative: RSU awards $ 22,384 $ 23,928 $ 67,150 $ 108,040 Stock Options 7,216 (10,912 ) 48,988 36,784 General and administrative stock-based compensation expense 29,600 13,016 116,138 144,824 Research and development: RSU awards 1,898 6,021 5,694 39,608 Stock Options 598 21,638 1,794 84,323 Research and development stock-based compensation expense 2,496 27,659 7,488 123,931 Total stock-based compensation expense $ 32,096 $ 40,675 $ 123,626 $ 268,755	For the years ended December 31, 2022 and 2021, the Company recorded stock -based Year Ended 2022 2021 General and administrative: RSU awards $ 130,689 $ 412,214 Stock Options 44,000 — General and administrative stock-based compensation expense 174,689 412,214 Research and development: RSU awards 41,506 58,664 Stock Options 84,921 — Research and development stock-based compensation expense 126,427 58,664 Total stock-based compensation expense $ 301,116 $ 470,878

Warrants (Tables)

Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Warrants [Abstract]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model	The fair value of the Rollover Warrants were estimated using the Black -Scholes Volatility 115 % Expected term (years) 6 Risk-free interest rate 0.85 % Expected dividend yield 0.0 % -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 % -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 %	The fair value of the Rollover Warrants was estimated using the Black -Scholes Volatility 115 % Expected term (years) 6 Risk-free interest rate 0.85 % Expected dividend yield 0.0 % -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % -Scholes Volatility 47 % Expected term (years) 5 Risk-free interest rate 1.54 % Expected dividend yield 0.0 % -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 % -Scholes Volatility 144 % Expected term (years) 5 Risk-free interest rate 2.69 % Expected dividend yield 0.0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Schedule of Provision for Income Taxes and Income Taxes Computed Using the Effective U.S. Federal Statutory Rate	The difference between the provision for income taxes and income taxes computed using the effective U.S. federal statutory rate is as follows: Year Ended 2022 2021 Federal tax statutory rate 21.0 % 21.0 % State tax, net of federal benefit 7.2 7.1 Research and development credits 0.6 1.9 Non-deductible expenses 2.9 (2.3 ) Change in valuation allowance (31.7 ) (27.7 ) Effective tax rate — % — %
Schedule of Deferred Tax Assets	Significant components of the Company’s deferred tax assets are as follows: Year Ended 2022 2021 Net operating loss carryforwards $ 5,511,086 $ 3,524,526 Research and development credits 324,661 255,656 Capitalized research and development costs 1,429,419 — Capitalized start-up costs 860,853 — Other, net 373,936 351,836 Total gross deferred tax assets 8,499,983 4,132,018 Valuation allowance (8,499,983 ) (4,132,018 ) Net deferred tax assets $ — $ —

Organization and Basis of Pre_2

Organization and Basis of Presentation (Details) - USD ($)			3 Months Ended						9 Months Ended		12 Months Ended
	Feb. 28, 2023	Jan. 30, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Aug. 08, 2023	Feb. 16, 2023	Feb. 13, 2023
Organization and Basis of Presentation [Line Items]
Common stock, shares authorized			500,000,000						500,000,000
Conversion of stock, shares converted		35									35
Converted shares of common stock		1									1
Net loss			$ (2,628,376)	$ (1,448,170)	$ 6,159,195	$ (1,170,736)	$ (1,834,686)	$ (6,616,541)	$ 2,082,649	$ (9,621,963)	$ (10,829,549)	$ (11,986,837)
Accumulated deficit											25,300,000
Stockholders' equity			8,818,523	$ 11,414,803	$ 10,017,646	$ 2,227,678	$ (1,843,009)	$ (98,511)	$ 8,818,523	$ 2,227,678	1,052,453	(99,470)
Cash and cash equivalents											5,300,000
Units separated into common stock and public warrant description									On January 13, 2023, the Company’s units were mandatorily separated into one share of common stock and one Public Warrant and ceased trading on the Nasdaq Capital Market (see Note 9).
Bid price of common stock per share													$ 1
Closing bid price of common stock per share													$ 1
Accumulated deficit			(23,264,199)						$ (23,264,199)		(25,346,848)	(14,517,299)
Cash and cash equivalents			$ 13,994,537						$ 13,994,537		$ 5,252,979	$ 1,274,729
Minimum [Member]
Organization and Basis of Presentation [Line Items]
Common stock, shares authorized		100,000,000
Maximum [Member]
Organization and Basis of Presentation [Line Items]
Common stock, shares authorized		500,000,000
Subsequent Event [Member]
Organization and Basis of Presentation [Line Items]
Common stock, shares authorized		500,000,000									500,000,000
Subsequent Event [Member] | IPO [Member]
Organization and Basis of Presentation [Line Items]
Net proceeds	$ 14,000,000
Subsequent Event [Member] | Minimum [Member]
Organization and Basis of Presentation [Line Items]
Common stock, shares authorized		100,000,000
Stockholders' equity														$ 2,500,000	$ 2,500,000
Subsequent Event [Member] | Maximum [Member]
Organization and Basis of Presentation [Line Items]
Common stock, shares authorized		500,000,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	5 years		5 years		5 years
Unrecognized tax benefits (in Dollars) | $	$ 0		$ 0
Potential shares of common stock	1,169,255	661,432	166,463,000,000	661,432	660,956	17,946
Number of operating segment			1		1
Class C Common Stock Warrant [Member]
Summary of Significant Accounting Policies [Line Items]
common stock issuable			163,457
Rollover Restricted Stock Unit Awards [Member]
Summary of Significant Accounting Policies [Line Items]
common stock issuable			3,006

Business Combination (Details)

Business Combination (Details) - USD ($)						9 Months Ended	12 Months Ended
	Feb. 22, 2022	Feb. 10, 2022	Feb. 04, 2022	Jan. 06, 2022	Dec. 21, 2021	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Business Combination (Details) [Line Items]
Common stock, per share						$ 0.001
Aggregate shares of common stock							87,797
Issuance shares of common stock						1,202,538		719,662
Shares of common stock outstanding							369,836
Shares of petra’s common stock					$ 4,500,000
Petra’s common stock, per share					$ 0.001
Aggregate shares of petra Common Stock				12,345
Surrendered for redemption total				$ 4,500,000
Shares of common stock of business combination							21,429
Business combination per share							$ 357.1
Shares of petra common stock exercised							99,449
Cash price per share							$ 357.1
Aggregate of payments							$ 35,500,000
Forward share purchase agreement						$ 7,700,000	7,700,000
Revelation amount						$ 4,200,000	4,200,000
Company paid	$ 691,392	$ 105,490
Total principal							750,000
Accrued interest of time of repayment							$ 46,882
Forward Share Purchase Agreement [Member]
Business Combination (Details) [Line Items]
Shares repurchased			21,429
Escrowed paid			$ 7,700,000
Petra [Member] | Common Stock [Member]
Business Combination (Details) [Line Items]
Ownership percentage							23.70%
Meteora [Member]
Business Combination (Details) [Line Items]
Shares of common stock of business combination							21,429
Escrowed paid			$ 7,700,000
Rollover Warrants Outstanding [Member]
Business Combination (Details) [Line Items]
Issuance shares of common stock							4,792
RSU [Member]
Business Combination (Details) [Line Items]
Issuance shares of common stock							13,154
Business Combination [Member]
Business Combination (Details) [Line Items]
Common stock, per share							$ 0.001
Shares of common stock							300,000
Aggregate shares of common stock							282,039
Redeemed from trust account					$ 31,500,000

Balance Sheet Details (Details)

Balance Sheet Details (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jul. 09, 2022	Jun. 30, 2022
Balance Sheet Details [Abstract]
Depreciation expense	$ 6,262	$ 6,262	$ 18,787	$ 18,786	$ 25,048	$ 16,782
Shares issued (in Shares)	6,297,303		6,297,303		682,882	282,039	8,572
Accrued professional fees								$ 700,000
Accrued other expenses					$ 5,000

Balance Sheet Details (Detail_2

Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid clinical costs	$ 71,250		$ 488,614
Other prepaid expenses & current assets	81,387	73,132	148,728
Total prepaid expenses & current assets	$ 152,637	$ 73,132	$ 637,342

Balance Sheet Details (Detail_3

Balance Sheet Details (Details) - Schedule of Property and Equipment, Net - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Property and Equipment, Net [Abstract]
Lab equipment	$ 131,963	$ 131,963	$ 131,963
Total property and equipment, gross	131,963	131,963	131,963
Accumulated depreciation	(60,617)	(41,830)	(16,782)
Total property and equipment, net	$ 71,346	$ 90,133	$ 115,181

Balance Sheet Details (Detail_4

Balance Sheet Details (Details) - Schedule of Accrued Expenses - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Accrued Expenses [Abstract]
Accrued payroll and related expenses	$ 507,579	$ 618,014	$ 756,729
Accrued clinical study expenses	31,661	175,061	327,244
Accrued professional fees	223,358	75,722	294,130
Accrued clinical development costs	259,437	111,700	145,566
Accrued other expenses		5,000	5,000
Total accrued expenses	$ 1,022,035	$ 985,497	$ 1,528,669

Commitments and Contingencies (

Commitments and Contingencies (Details) £ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Feb. 18, 2022 USD ($)

Jan. 10, 2022 USD ($)

Jan. 06, 2022 shares

Oct. 31, 2021 USD ($)

Feb. 28, 2021 USD ($) ft²

Sep. 30, 2023 USD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2023 USD ($)

Sep. 30, 2022 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Jan. 31, 2023 USD ($)

Jan. 30, 2023 USD ($)

Dec. 31, 2022 GBP (£)

Sep. 27, 2022 GBP (£)

Jan. 04, 2022 USD ($) shares

Commitments and Contingencies [Line Items]

Security deposit required to maintain

$ 5,564

Rent expense

$ 28,890

$ 17,193

$ 82,771

$ 49,453

$ 66,645

$ 55,246

Common stocks transferred shares (in Shares) | shares

12,345

Aggregate shares purchased shares (in Shares) | shares

7,001

7,001

Interest incurred

$ 0

$ 14,383

14,383

Unpaid banking advisory fees

$ 2,700,000

Unpaid banking advisory fees in form of equity

2,600,000

Transaction expenses

8,500,000

Deferred underwriting fees

1,500,000

Repayments of initial public offering

$ 655,000

655,000

Unpaid invoices, plus interest and costs (in Pounds) | £

£ 1.6

£ 1.6

Damage amount, plus interest

$ 150,000

Rent

$ 9,630

Directors and Officers Liability Insurance [Member]

Commitments and Contingencies [Line Items]

Total expense incurred for upfront, monthly and interest payments

834,856

Interest payments

834,856

Premium finance agreement

0

Convertible Debt [Member]

Commitments and Contingencies [Line Items]

Debt instrument face amount

$ 2,500,000

Fixed annual interest rate

10%

10%

Convertible Debt [Member] | Maximum [Member]

Commitments and Contingencies [Line Items]

Debt instrument face amount

$ 2,500,000

Original Lease [Member]

Commitments and Contingencies [Line Items]

Area square feet (in Square Feet) | ft²

2,140

Borrowing rate, percentage

7.73%

Operating lease option to extend

There was no option to extend the Original Lease

Security deposit required to maintain

$ 5,564

Future minimum lease payments

$ 70,313

First Amendment [Member]

Commitments and Contingencies [Line Items]

Future minimum lease payments

$ 51,578

$ 0

Operating lease expiration date

Dec. 31, 2022

Second Amendment [Member]

Commitments and Contingencies [Line Items]

Future minimum lease payments

$ 28,890

$ 28,890

Petra common stock [Member] | Convertible Debt [Member]

Commitments and Contingencies [Line Items]

Common stocks transferred shares (in Shares) | shares

7,001

PremiumFinanceAgreementMember | Directors and Officers Liability Insurance [Member]

Commitments and Contingencies [Line Items]

Debt instrument face amount

$ 825,000

Fixed annual interest rate

3.57%

Monthly payable amount

$ 9,856

Monthly payments

$ 74,428

Number of monthly installments

9

Debt instrument, frequency of periodic payment

monthly

Debt instrument maturity date

Oct. 10, 2022

Upfront payment due

$ 165,000

PIPE Investment (Details)

PIPE Investment (Details) - USD ($)				9 Months Ended	12 Months Ended
	Feb. 22, 2022	Jan. 25, 2022	Jan. 23, 2022	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for issuance (in Shares)				1,202,538			719,662
Warrant exercise price				$ 5.36
Aggregate value (in Dollars)					$ 301,116	$ 470,878
Placement Agent [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for issuance (in Shares)				10,347	10,347
Warrant exercise price				$ 115.15
Cash fee, percentage				6%	6%
Issuance costs (in Dollars)				$ 465,600	$ 465,600
Common stock, percentage					7%
Warrants and rights expiration date				Jul. 25, 2027
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of shares (in Shares)		36,947
Net proceeds (in Dollars)		$ 7,300,000
Aggregate value (in Dollars)				$ 500,000	$ 500,000
Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of shares (in Shares)	36,959		36,959
Warrant exercise price					$ 0.00035
Purchase price	$ 12.94
Class A Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock reserved for issuance (in Shares)		73,905	73,905	73,905			73,905
Warrant exercise price		$ 115.15		$ 115.15	$ 115.15		$ 115.15
Purchase price		$ 105
Aggregate value (in Dollars)					$ 3,600,000
Warrants and rights expiration date		Jul. 25, 2027
Class A Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of shares (in Shares)	36,959	36,959
Warrant exercise price		$ 0.00035		$ 0.00035
Purchase price	$ 12.94	$ 104.99965
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase of shares (in Shares)			36,947
Gross purchase price			$ 105
Net proceeds (in Dollars)			$ 7,300,000
Percentage of exceeds percentage					9.99%
Securities Purchase Agreement [Member] | Pre-Funded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Gross purchase price					$ 105
Warrant exercise price					$ 0.00035
Outstanding common stock, percentage					9.99%
Securities Purchase Agreement [Member] | Class A Common Stock Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price					$ 115.15
Percentage of exceeds percentage					4.99%

Public Offering (Details)

Public Offering (Details) - USD ($)			9 Months Ended
	Feb. 13, 2023	Jul. 28, 2022	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Public Offering (Details) [Line Items]
Issuance of common stock	2,888,600	238,096
Warrants to purchase		8,333,334
Warrant exercise price, per share			$ 5.36
Net proceeds received from public offering		$ 4,500,000	$ 14,000,000
Percentage of cash fee		7%	8%
Public offering cost		$ 350,000	$ 1,200,000
July 2022 Public Offering [Member]
Public Offering (Details) [Line Items]
Warrants to purchase		8,333,334
Class B Common Stock Warrants [Member]
Public Offering (Details) [Line Items]
Warrants to purchase		238,095	8,333,334	8,333,334
Warrant exercise price, per share		$ 21	$ 21	$ 21	$ 21
Warrant exercise price, per share		$ 21
Common stock aggregate amount		$ 4,500,000
Warrants and rights expiration date		Jul. 28, 2027
July 2022 Public Offering [Member]
Public Offering (Details) [Line Items]
Warrants and rights expiration period		5 years
Placement Agent Warrants [Member]
Public Offering (Details) [Line Items]
Warrants to purchase		16,667
Class B Placement Agent Common Stock Warrants [Member]
Public Offering (Details) [Line Items]
Warrants to purchase		16,667	16,667	16,667
Warrant exercise price, per share		$ 26.25	$ 26.25	$ 26.25	$ 26.25
Warrants and rights expiration period		5 years
Percentage of shares sold in public offering		7%
Common stock aggregate amount		$ 300,000
Warrants and rights expiration date		Jul. 25, 2027

Preferred Stock (Details)

Preferred Stock (Details) - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2020	Sep. 30, 2023	Dec. 31, 2022	Jan. 30, 2023	Dec. 19, 2022	Dec. 31, 2021	Aug. 31, 2020
Preferred Stock (Details) [Line Items]
Preferred stock, shares authorized								2,000,000
Preferred stock, per share (in Dollars per share)								$ 0.001
Board of Directors [Member]
Preferred Stock (Details) [Line Items]
Preferred stock, shares authorized			5,000,000	5,000,000
Preferred stock, per share (in Dollars per share)			$ 0.001	$ 0.001
Series A Preferred Stock [Member]
Preferred Stock (Details) [Line Items]
Preferred stock, shares authorized			0	1			0
Preferred stock, per share (in Dollars per share)			$ 0.001	$ 0.001		$ 0.001	$ 0.001
Cash paid to purchaser (in Dollars)			$ 0	$ 5,000		$ 5,000	$ 0
Preferred stock, vote			50,000,000	50,000,000
Preferred stock was redeemed (in Dollars)				$ 5,000	$ 5,000
Preferred stock converted								48,971
Shares issued		628,930
Net proceeds (in Dollars)		$ 3,900,000
Shares of common stock		48,971
Series A-1 Preferred Stock [Member]
Preferred Stock (Details) [Line Items]
Preferred stock converted								53,293
Shares issued	684,450
Net proceeds (in Dollars)	$ 3,900,000
Shares of common stock	53,293

Units (Details)

Units (Details) - $ / shares		9 Months Ended	12 Months Ended
	Jan. 13, 2023	Sep. 30, 2023	Dec. 31, 2022	Oct. 31, 2020
Units (Details) [Line Items]
Units outstanding			48,246
Warrant issuing, description		October of 2020, Petra issued unit’s that consisted of one share of common stock and one warrant exercisable for 1/35 of a share of common stock with an exercise price of $402.50 per share which expire on January 10, 2027 (the “Public Warrants”), which traded on the Nasdaq Capital Market under the ticker symbol REVBU.
Number of units separation	1,688,598
IPO [Member]
Units (Details) [Line Items]
Share price (in Dollars per share)				$ 402.5
Common Stock [Member]
Units (Details) [Line Items]
Number of units separation	48,246
Number of new shares issued
Public Warrants [Member]
Units (Details) [Line Items]
Warrants	1,688,598
Number of new shares issued

Common Stock (Details)

Common Stock (Details) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 18, 2023

Apr. 06, 2023

Mar. 02, 2023

Feb. 14, 2023

Feb. 13, 2023

Feb. 01, 2023

Jul. 29, 2022

Jul. 28, 2022

Feb. 22, 2022

Feb. 04, 2022

Feb. 02, 2022

Jan. 25, 2022

Jan. 23, 2022

Mar. 31, 2023

Apr. 06, 2023

Jun. 30, 2023

Sep. 30, 2023

Dec. 31, 2022

Dec. 31, 2021

Jan. 30, 2023

Jul. 09, 2022

Jan. 31, 2022

Common Stock [Line Items]

Common stock, shares authorized

500,000,000

Common stock, par value (in Dollars per share)

$ 0.001

Reverse stock ratio

1-for-35

Reverse stock split term

As a result of the Reverse Split, every 35 shares of the Company’s issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share. No fractional shares were outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock automatically received an additional fraction of a share of common stock to round up to the next whole share. In addition, effective as of the same time as the Reverse Split, proportionate adjustments were made to all then-outstanding equity awards and warrants with respect to the number of shares of common stock subject to such award or warrant and the exercise price thereof. Furthermore, the number of shares of common stock available for issuance under the Company’s equity incentive plans were proportionately adjusted for the Reverse Split ratio, such that fewer shares will be subject to such plans.

Common stock aggregate shares

87,797

Proceeds from business combination (in Dollars)

$ 11,900,000

$ 11,900,000

Escrowed amount (in Dollars)

7,700,000

7,700,000

Released amount (in Dollars)

$ 4,200,000

4,200,000

Net proceeds from sale and issuance of common stock (in Dollars)

$ 599,996

Common stock, shares issued

6,297,303

682,882

282,039

8,572

Common stock, shares outstanding

6,297,303

682,882

282,039

Cash (in Dollars)

$ 0

$ 0

Warrant [Member]

Common Stock [Line Items]

Purchase price (in Dollars per share)

$ 5,073

Warrants shares

54

4,738

Purchase price (in Dollars)

$ 5,073

Class A Pre-Funded Warrants [Member]

Common Stock [Line Items]

Common stock, shares issued

36,959

36,959

Purchase price (in Dollars per share)

$ 12.94

$ 104.99965

Warrants shares

36,959

Class C Pre-Funded Warrants [Member]

Common Stock [Line Items]

Common stock, shares issued

143,400

160,000

33,000

Purchase price (in Dollars per share)

$ 14.34

$ 16

$ 3.3

$ 0.0001

$ 33.64

Minimum [Member]

Common Stock [Line Items]

Common stock, shares authorized

100,000,000

Maximum [Member]

Common Stock [Line Items]

Common stock, shares authorized

500,000,000

Pre-Funded Warrant [Member]

Common Stock [Line Items]

Common stock, shares issued

36,959

Purchase price (in Dollars per share)

$ 12.94

Warrant [Member]

Common Stock [Line Items]

Purchase price (in Dollars per share)

$ 5,073

Warrants shares

54

4,738

Purchase price (in Dollars)

$ 5,073

July 2022 Public Offering Member

Common Stock [Line Items]

Common stock, shares issued

238,096

Net proceeds from sale and issuance of common stock (in Dollars)

$ 4,500,000

February 2023 Public Offering [Member]

Common Stock [Line Items]

Common stock, shares issued

2,888,600

965,357

1,419,780

Net proceeds from sale and issuance of common stock (in Dollars)

$ 14,000,000

CommonStockIssuanceMember

Common Stock [Line Items]

Common stock, shares issued

8,572

SecuritiesPurchaseAgreementMember

Common Stock [Line Items]

Common stock, shares issued

36,947

Net proceeds from sale and issuance of common stock (in Dollars)

$ 7,300,000

ForwardSharePurchaseAgreementMember

Common Stock [Line Items]

Shares repurchased

21,429

Shares amount repurchased escrowed and returned (in Dollars)

$ 7,700,000

Subsequent Event [Member]

Common Stock [Line Items]

Common stock, shares authorized

500,000,000

500,000,000

Common stock, par value (in Dollars per share)

$ 0.001

$ 0.001

Reverse stock ratio

reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one-for-twenty (1-for-20) to a maximum of a one-for-one hundred (1-for-100) split

Reverse stock split term

As a result of the Reverse Split, every 35 shares of the Company’s issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share. No fractional shares are outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock automatically received an additional fraction of a share of common stock to round up to the next whole share. In addition, effective as of the same time as the Reverse Split, proportionate adjustments were made to all then-outstanding equity awards and warrants with respect to the number of shares of common stock subject to such award or warrant and the exercise price thereof. Furthermore, the number of shares of common stock available for issuance under the Company’s equity incentive plans were proportionately adjusted for the Reverse Split ratio, such that fewer shares will be subject to such plans.

Subsequent Event [Member] | Minimum [Member]

Common Stock [Line Items]

Common stock, shares authorized

100,000,000

Subsequent Event [Member] | Maximum [Member]

Common Stock [Line Items]

Common stock, shares authorized

500,000,000

Restricted Stock [Member]

Common Stock [Line Items]

Vested Rollover RSU Awards

4,284

3,435

Business Combination [Member]

Common Stock [Line Items]

Common stock aggregate shares

282,039

282,039

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance - shares	Dec. 31, 2022	Dec. 31, 2021
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	719,663	17,946
Revelation Sub Series A Preferred Stock [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance
Series A-1 Preferred Stock [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance
Public Warrants [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	300,332
Class A Common Stock Warrants [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	73,905
Class A Placement Agent Common Stock Warrants [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	10,347
Class B Common Stock Warrants [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	238,096
Class B Placement Agent Common Stock Warrants [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	16,667
Rollover Warrants [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	4,738	4,792
Unvested and Unissued Rollover RSU awards [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	7,290	13,154
Share-Based Payment Arrangement, Option [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	9,581
Dilutive shares [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	660,956	17,946
Stock grants under two thousand twenty one Equity Plan [Member]
Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Total common stock reserved for issuance	58,707

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)		9 Months Ended	12 Months Ended
	Jul. 29, 2022 Employee shares	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Jan. 01, 2023 shares	Jan. 31, 2022 shares	Jan. 01, 2022	Dec. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of aggregate number of outstanding shares of common stock						10%
Weighted-average Black-Scholes value per stock option | $ / shares		$ 10.47	$ 25.67
2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares available for grant			0
Two Thousand and Twenty One Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized				68,288	36,983
Shares available for future grant		33,283	58,707
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year	1 year
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years	4 years
Board of Directors Chairman [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price based on estimated fair market value of common stock		100%	100%
Subsequent Event [Member] | Two Thousand and Twenty One Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized				68,288
Restricted Stock Units (RSUs) [Member] | 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, granted			13,154
Incentive Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable period		5 years	5 years
Incentive Stock Options [Member] | Scenario One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price based on estimated fair market value of common stock		110%	110%
Time-Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting, description			Under time-based vesting conditions, the Rollover RSU awards vest quarterly over one year for grants to the Board of Directors and quarterly over four years or 25% on the one year anniversary and the remainder vesting monthly thereafter for grants to officers, employees and consultants.
Rollover Restricted Stock Units Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year 4 months 24 days	2 years 4 months 24 days
Awards outstanding		3,006	7,290				13,154
Awards vested, and unissued		1,371	3,435
Awards, forfeited			2,429
Awards, expected to vest		1,635	7,290
Unrecognized stock-based compensation expense related to awards | $		$ 131,185	$ 204,030
Unrecognized stock-based compensation expense, expected period for recognition		1 year 4 months 24 days	2 years 1 month 6 days
Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, granted		25,424	15,708
Vesting, description		(i) vest fully on the date of grant; (ii) vest 25% on the one year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter; or (iii) vest quarterly over one year, for grants to Board of Directors, officers and employees.	which vest 25% on the one year anniversary of the grant date or the employees hiring date, with the remainder vesting quarterly thereafter for grants to officers and employees.
Vesting percentage	100%
Number of employees | Employee	9
Shares, Granted	5,590
Unrecognized stock-based compensation expense related to stock options | $		$ 75,191	$ 98,633
Stock options, maximum term	3 years	10 years	10 years
Unrecognized stock-based compensation expense, expected period for recognition		2 years 4 months 24 days	3 years 2 months 12 days
Stock options, minimum term		3 years
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25%	25%
Time-based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting, description		Under time-based vesting conditions, the Rollover RSU awards vest quarterly over one year for grants to the Board of Directors and quarterly over four years or 25% on the one year anniversary and the remainder vesting monthly thereafter for grants to officers, employees and consultants.
Time-based Restricted Stock Units [Member] | Board of Directors Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Vesting, description		RSU awards vest quarterly over one year for grants to the Board of Directors
Time-based Restricted Stock Units [Member] | Officers, Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting, description		quarterly over four years or 25% on the one year anniversary and the remainder vesting monthly thereafter for grants to officers, employees and consultants
Time-based Restricted Stock Units [Member] | Officers, Employees and Consultants [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25%
Time-based Restricted Stock Units [Member] | Scenario Two [Member] | Officers, Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Stock Options Activity - Share-Based Payment Arrangement, Option [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation (Details) - Schedule of Stock Options Activity [Line Items]
Shares Outstanding, Ending Balance (in Shares)	35,005	9,581
Weighted-average Exercise Price, Ending Balance	$ 9.6	$ 31.91
Weighted-average Remaining Contractual Term (Years), Ending Balance	8 years 2 months 12 days	3 years 6 months
Shares, Exercisable (in Shares)	32,514	5,590
Weighted-average Exercise Price, Exercisable	$ 6.58	$ 19.71
Weighted-average Remaining Contractual Term, Exercisable	8 years 2 months 12 days	2 years 7 months 6 days
Shares, Granted (in Shares)	25,424	15,708
Weighted-average Exercise Price, Granted	$ 1.19	$ 38.57
Shares, Exercised (in Shares)
Weighted-average Exercise Price, Exercised
Shares, Expired and forfeited (in Shares)		(6,127)
Weighted-average Exercise Price, Expired and forfeited		$ 49

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Assumptions used in Estimating Fair Value of Stock Options - Share-Based Payment Arrangement, Option [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	126%	96.50%
Expected term (years)	5 years 10 days	5 years
Risk-free interest rate	3.09%	2.27%
Expected dividend yield	0%	0%

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 301,116	$ 470,878
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	174,689	412,214
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	126,427	58,664
Restricted Stock Units [Member] | General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	130,689	412,214
Restricted Stock Units [Member] | Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	41,506	$ 58,664
Stock Options [Member] | General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	44,000
Stock Options [Member] | Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 84,921

Warrants (Details)

Warrants (Details) - USD ($)									2 Months Ended	3 Months Ended		7 Months Ended	9 Months Ended		12 Months Ended
	Apr. 06, 2023	Mar. 02, 2023	Feb. 14, 2023	Feb. 13, 2023	Jul. 28, 2022	Feb. 22, 2022	Feb. 02, 2022	Jan. 25, 2022	Apr. 06, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jan. 13, 2023	Jul. 09, 2022	Dec. 31, 2021
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock					8,333,334
Common stock aggregate shares															87,797
Warrant exercise price (in Dollars per share)										$ 5.36		$ 5.36	$ 5.36
Aggregate amount (in Dollars)															$ 326,675
Shares of common stock				2,888,600	238,096
Warrants outstanding															48,246
Fair value (in Dollars)										$ (92,561)			$ (8,260,735)
Issuance of common stock										6,297,303		6,297,303	6,297,303		682,882		8,572	282,039
Public Warrants [Member]
Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share)										$ 402.5	$ 402.5	$ 402.5	$ 402.5	$ 402.5
Public warrant price per share (in Dollars per share)													$ 0.01		$ 0.01
Warrants shares																1,688,598
Public Warrants [Member] | IPO [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock										10,511,597		10,511,597	10,511,597		10,511,597
Common stock aggregate shares													300,332		300,332
Warrant exercise price (in Dollars per share)										$ 402.5		$ 402.5	$ 402.5		$ 402.5
Warrant expiration date										Jan. 10, 2027		Jan. 10, 2027	Jan. 10, 2027		Jan. 10, 2027
Rollover Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock										4,792		4,792	4,792
Warrant exercise price (in Dollars per share)										$ 93.8	93.8	$ 93.8	$ 93.8	93.8
Warrant expiration date										Jan. 31, 2027		Jan. 31, 2027	Jan. 31, 2027		Jan. 31, 2027
Aggregate amount (in Dollars)													$ 326,675
Class A Common Stock Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock										73,905		73,905	73,905		73,905
Warrant exercise price (in Dollars per share)								$ 115.15		$ 115.15	115.15	$ 115.15	$ 115.15	115.15	$ 115.15
Warrant expiration date										Jul. 25, 2027		Jul. 25, 2027	Jul. 25, 2027		Jul. 25, 2027
Public warrant price per share (in Dollars per share)								105
Aggregate amount (in Dollars)													$ 3,600,000		$ 3,634,262
Pre Funded Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock															36,959
Warrant exercise price (in Dollars per share)															$ 0.00035
Public warrant price per share (in Dollars per share)						$ 12.94
Warrants shares						36,959
Class A Placement Agent Common Stock Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock										10,347		10,347	10,347		10,347
Warrant exercise price (in Dollars per share)										$ 115.15	115.15	$ 115.15	$ 115.15	115.15	$ 115.15
Warrant expiration date										Jul. 25, 2027		Jul. 25, 2027	Jul. 25, 2027		Jul. 25, 2027
Aggregate amount (in Dollars)													$ 500,000		$ 508,797
Class B Common Stock Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock					238,095					8,333,334		8,333,334	8,333,334		8,333,334
Common stock aggregate shares													238,095		238,095
Warrant exercise price (in Dollars per share)					$ 21					$ 21	21	$ 21	$ 21	21	$ 21
Warrant expiration date										Jul. 28, 2027		Jul. 28, 2027	Jul. 28, 2027		Jul. 28, 2027
Aggregate amount (in Dollars)													$ 4,500,000		$ 4,490,457
Class B Placement Agent Common Stock Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock					16,667					16,667		16,667	16,667		16,667
Warrant exercise price (in Dollars per share)					$ 26.25					$ 26.25	26.25	$ 26.25	$ 26.25	26.25	$ 26.25
Warrant expiration date										Jul. 25, 2027		Jul. 25, 2027	Jul. 25, 2027		Jul. 25, 2027
Aggregate amount (in Dollars)													$ 300,000		$ 310,137
Warrant [Member]
Warrants (Details) [Line Items]
Public warrant price per share (in Dollars per share)							$ 5,073
Warrants shares							54			4,738		4,738	4,738
Class A Pre-Funded Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock										36,959		36,959	36,959
Warrant exercise price (in Dollars per share)								0.00035		$ 0.00035		$ 0.00035	$ 0.00035
Public warrant price per share (in Dollars per share)						$ 12.94		$ 104.99965
Warrants shares						36,959
Class C Pre-Funded Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock			336,400
Warrant exercise price (in Dollars per share)			$ 0.0001	$ 4.8299
Public warrant price per share (in Dollars per share)	$ 14.34	$ 16	$ 3.3	0.0001					$ 33.64
Shares of common stock									336,400
Warrants outstanding
Class C Pre-Funded Warrants [Member] | Note Warrant [Member]
Warrants (Details) [Line Items]
Warrants outstanding													0
Class C Common Stock Warrant [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock										6,450,000		6,450,000	6,450,000
Warrant exercise price (in Dollars per share)				$ 4.83						$ 5.36	$ 5.36	$ 5.36	$ 5.36	$ 5.36
Warrant expiration date										Feb. 14, 2028		Feb. 14, 2028	Feb. 14, 2028
Aggregate amount (in Dollars)													$ 13,996,500
Warrants shares										5,962,840		5,962,840	5,962,840
Shares of common stock				6,450,000								2,385,137
Fair value (in Dollars)										$ 100,000			$ 8,300,000
Issuance of common stock										2,385,137		2,385,137	2,385,137
Warrants outstanding										487,160		487,160	487,160
Fair value (in Dollars)										$ 200,000		$ 200,000	$ 200,000
Class C Common Stock Warrant [Member] | Warrant [Member]
Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share)										$ 0.4		$ 0.4	$ 0.4
Fair value (in Dollars)													$ 14,000,000
Minimum [Member] | Public Warrants [Member]
Warrants (Details) [Line Items]
Exceeds price per share (in Dollars per share)										$ 630		$ 630	$ 630		$ 630
Sub Series A-1 Preferred Stock [Member] | Rollover Warrants [Member]
Warrants (Details) [Line Items]
Warrants to purchase an aggregate shares of common stock															4,792
Warrant exercise price (in Dollars per share)															$ 93.8
Common Stock [Member]
Warrants (Details) [Line Items]
Issuance of common stock										6,297,303		6,297,303	6,297,303		682,882			282,039
Common Stock [Member] | Class C Common Stock Warrant [Member]
Warrants (Details) [Line Items]
Warrant exercise price (in Dollars per share)										$ 0.4		$ 0.4	$ 0.4
Warrant [Member]
Warrants (Details) [Line Items]
Public warrant price per share (in Dollars per share)							$ 5,073
Warrants shares							54								4,738

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Rollover Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	115%	115%
Expected term (years)	6 years	6 years
Risk-free interest rate	0.85%	0.85%
Expected dividend yield	0%	0%
Class A Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	47%	47%
Expected term (years)	5 years	5 years
Risk-free interest rate	1.54%	1.54%
Expected dividend yield	0%	0%
Class A Placement Agent Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	47%	47%
Expected term (years)	5 years	5 years
Risk-free interest rate	1.54%	1.54%
Expected dividend yield	0%	0%
Class B Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	144%	144%
Expected term (years)	5 years	5 years
Risk-free interest rate	2.69%	2.69%
Expected dividend yield	0%	0%
Class B Placement Agent Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	144%	144%
Expected term (years)	5 years	5 years
Risk-free interest rate	2.69%	2.69%
Expected dividend yield	0%	0%

Income Taxes (Details)

Income Taxes (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 27, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Valuation allowance						$ 8,499,983	$ 4,132,018
Valuation allowance increased						4,012,802	3,323,197
Unrecognized tax benefits		$ 0		$ 0
Accrued interest or penalties
Taxable income percentage	80%
Provision for income tax benefit
Non-taxable income		$ 100,000		$ 8,300,000
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Federal and state net operating loss carryforwards						18,224,037	12,468,027
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Federal and state net operating loss carryforwards						$ 24,505,008	13,221,253
State net operating loss carryforwards expire						2026
Research Tax Credit Carryforward [Member] | Domestic Tax Authority [Member]
Income Taxes [Line Items]
Research and development credit carryforwards						$ 93,915	91,217
Federal research and development credit carryforwards expire						2040
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Research and development credit carryforwards						$ 292,083	$ 208,150

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Provision for Income Taxes and Income Taxes Computed Using the Effective U.S. Federal Statutory Rate	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Provision For Income Taxes And Income Taxes Computed Using The Effective USFederal Statutory Rate Abstract
Federal tax statutory rate	21%	21%
State tax, net of federal benefit	7.20%	7.10%
Research and development credits	0.60%	1.90%
Non-deductible expenses	2.90%	(2.30%)
Change in valuation allowance	(31.70%)	(27.70%)
Effective tax rate

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Deferred Tax Assets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Deferred Tax Assets Abstract
Net operating loss carryforwards	$ 5,511,086	$ 3,524,526
Research and development credits	324,661	255,656
Capitalized research and development costs	1,429,419
Capitalized start-up costs	860,853
Other, net	373,936	351,836
Total gross deferred tax assets	8,499,983	4,132,018
Valuation allowance	(8,499,983)	(4,132,018)
Net deferred tax assets

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)									1 Months Ended	7 Months Ended	9 Months Ended	12 Months Ended
	Mar. 02, 2023	Feb. 14, 2023	Feb. 13, 2023	Feb. 01, 2023	Jan. 30, 2023	Jan. 13, 2023	Jul. 28, 2022	Feb. 22, 2022	Jan. 31, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2023	Mar. 31, 2023	Mar. 20, 2023	Feb. 16, 2023	Feb. 15, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Subsequent Events [Line Items]
Monthly rent (in Dollars)									$ 9,630
Common stock, shares authorized										500,000,000	500,000,000
Description of the reverse stock split				1-for-35
Reverse stock split											As a result of the Reverse Split, every 35 shares of the Company’s issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share. No fractional shares were outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock automatically received an additional fraction of a share of common stock to round up to the next whole share. In addition, effective as of the same time as the Reverse Split, proportionate adjustments were made to all then-outstanding equity awards and warrants with respect to the number of shares of common stock subject to such award or warrant and the exercise price thereof. Furthermore, the number of shares of common stock available for issuance under the Company’s equity incentive plans were proportionately adjusted for the Reverse Split ratio, such that fewer shares will be subject to such plans.
Aggregate of shares			2,888,600				238,096
Common stock, par value (in Dollars per share)										$ 0.001	$ 0.001
Purchase warrants							8,333,334
Price per share (in Dollars per share)										$ 5.36	$ 5.36
Deferred offering costs (in Dollars)												$ 87,171
Net proceeds (in Dollars)							$ 4,500,000				$ 14,000,000
Gross proceeds percentage							7%				8%
Cash fee total amount (in Dollars)							$ 350,000				$ 1,200,000
Stockholders’ equity excess amount (in Dollars)										$ 8,818,523	$ 8,818,523	$ 1,052,453	$ (99,470)	$ 11,414,803	$ 10,017,646				$ 2,227,678	$ (1,843,009)	$ (98,511)
Shares of common stock												99,449
Public Warrants [Member]
Subsequent Events [Line Items]
Number of new shares issued
Price per share (in Dollars per share)										$ 402.5	$ 402.5								$ 402.5
Warrants issued						1,688,598
Purchase price per share (in Dollars per share)											$ 0.01	$ 0.01
Common Stock [Member]
Subsequent Events [Line Items]
Number of new shares issued
Aggregate of shares													450
Stockholders’ equity excess amount (in Dollars)										$ 6,297	$ 6,297	$ 683	$ 282	$ 6,297	$ 4,730				$ 683	$ 442	$ 442
Pre Funded Warrants [Member]
Subsequent Events [Line Items]
Purchase warrants												36,959
Price per share (in Dollars per share)												$ 0.00035
Warrants issued								36,959
Purchase price per share (in Dollars per share)								$ 12.94
Class C Common Stock Warrant [Member]
Subsequent Events [Line Items]
Aggregate of shares			6,450,000							2,385,137
Purchase warrants										6,450,000	6,450,000
Price per share (in Dollars per share)			$ 4.83							$ 5.36	$ 5.36								$ 5.36
Aggregate value of warrants (in Dollars)			$ 14,000,000
Per share price (in Dollars per share)			$ 5.36
Warrants issued										5,962,840	5,962,840
Minimum [Member]
Subsequent Events [Line Items]
Common stock, shares authorized					100,000,000
Maximum [Member]
Subsequent Events [Line Items]
Common stock, shares authorized					500,000,000
Public Offering [Member] | Public Warrants [Member]
Subsequent Events [Line Items]
Purchase warrants										10,511,597	10,511,597	10,511,597
Price per share (in Dollars per share)										$ 402.5	$ 402.5	$ 402.5
Common Stock [Member]
Subsequent Events [Line Items]
Common stock, shares authorized										500,000,000	500,000,000	500,000,000	11,000,000
Reverse stock split					1-for-35
Common stock, par value (in Dollars per share)										$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common Stock [Member] | Class C Common Stock Warrant [Member]
Subsequent Events [Line Items]
Price per share (in Dollars per share)										$ 0.4	$ 0.4
Subsequent Event [Member]
Subsequent Events [Line Items]
Number of units separation						1,688,598
Common stock, shares authorized					500,000,000							500,000,000
Description of the reverse stock split												reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one-for-twenty (1-for-20) to a maximum of a one-for-one hundred (1-for-100) split
Reverse stock split												As a result of the Reverse Split, every 35 shares of the Company’s issued and outstanding common stock automatically converted into one share of common stock, without any change in the par value per share. No fractional shares are outstanding following the Reverse Split. Any holder who would have received a fractional share of common stock automatically received an additional fraction of a share of common stock to round up to the next whole share. In addition, effective as of the same time as the Reverse Split, proportionate adjustments were made to all then-outstanding equity awards and warrants with respect to the number of shares of common stock subject to such award or warrant and the exercise price thereof. Furthermore, the number of shares of common stock available for issuance under the Company’s equity incentive plans were proportionately adjusted for the Reverse Split ratio, such that fewer shares will be subject to such plans.
Aggregate of shares			2,888,600
Common stock, par value (in Dollars per share)			$ 0.001									$ 0.001
Price per share (in Dollars per share)			$ 4.8299
Gross proceeds (in Dollars)			$ 15,600,000
Net proceeds (in Dollars)			$ 14,000,000
Gross proceeds percentage			8%
Cash fee total amount (in Dollars)			$ 1,200,000
Bid price (in Dollars per share)																	$ 1
Per share price (in Dollars per share)																		$ 1
Shares of common stock																747,357
Subsequent Event [Member] | Public Warrants [Member]
Subsequent Events [Line Items]
Number of new shares issued
Subsequent Event [Member] | Common Stock [Member]
Subsequent Events [Line Items]
Number of new shares issued
Subsequent Event [Member] | Pre Funded Warrants [Member]
Subsequent Events [Line Items]
Aggregate of shares			336,400
Price per share (in Dollars per share)			$ 0.0001
Warrants issued	160,000	33,000
Purchase price per share (in Dollars per share)	$ 16	$ 3.3
Subsequent Event [Member] | Class C Common Stock Purchase Warrants [Member]
Subsequent Events [Line Items]
Purchase warrants			6,450,000
Price per share (in Dollars per share)			$ 4.83
Subsequent Event [Member] | Class C Common Stock Warrant [Member]
Subsequent Events [Line Items]
Price per share (in Dollars per share)			$ 5.36
Expire term			5 years
Aggregate value of warrants (in Dollars)			$ 16,100,000
Warrants issued																1,868,390
Subsequent Event [Member] | Minimum [Member]
Subsequent Events [Line Items]
Common stock, shares authorized					100,000,000
Stockholders’ equity excess amount (in Dollars)			2,500,000														$ 2,500,000
Per share price (in Dollars per share)																		$ 1
Subsequent Event [Member] | Maximum [Member]
Subsequent Events [Line Items]
Common stock, shares authorized					500,000,000
Subsequent Event [Member] | Second Amendment [Member]
Subsequent Events [Line Items]
Lease expiration date									Dec. 31, 2023
Monthly rent (in Dollars)									$ 9,630
Rent expense (in Dollars)									$ 105,930
Subsequent Event [Member] | Public Offering [Member]
Subsequent Events [Line Items]
Net proceeds (in Dollars)			$ 14,000,000

Balance Sheet Details (Detail_5

Balance Sheet Details (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance costs	$ 71,250		$ 488,614
Other prepaid expenses & current assets	81,387	73,132	148,728
Total prepaid expenses & current assets	$ 152,637	$ 73,132	$ 637,342

Balance Sheet Details (Detail_6

Balance Sheet Details (Details) - Schedule of Property and Equipment, Net - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Property and Equipment, Net [Abstract]
Lab equipment	$ 131,963	$ 131,963	$ 131,963
Total property and equipment, gross	131,963	131,963	131,963
Accumulated depreciation	(60,617)	(41,830)	(16,782)
Total property and equipment, net	$ 71,346	$ 90,133	$ 115,181

Balance Sheet Details (Detail_7

Balance Sheet Details (Details) - Schedule of Accrued Expenses - USD ($)	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Accrued Expenses [Abstract]
Accrued payroll and related expenses	$ 507,579	$ 618,014	$ 756,729
Accrued clinical study expenses	31,661	175,061	327,244
Accrued professional fees	223,358	75,722	294,130
Accrued clinical development costs	259,437	111,700	145,566
Accrued other expenses		5,000	5,000
Total accrued expenses	$ 1,022,035	$ 985,497	$ 1,528,669

2023 Public Offering (Details)

2023 Public Offering (Details) - USD ($)						2 Months Ended	7 Months Ended	9 Months Ended	12 Months Ended
	Apr. 06, 2023	Mar. 02, 2023	Feb. 14, 2023	Feb. 13, 2023	Jul. 28, 2022	Apr. 06, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
2023 Public Offering [Line Items]
Issuance of common stock				2,888,600	238,096
Purchase price, per share (in Dollars per share)							$ 5.36	$ 5.36
Net cash proceeds (in Dollars)					$ 4,500,000			$ 14,000,000
Percentage of gross proceeds					7%			8%
Public offering cost (in Dollars)					$ 350,000			$ 1,200,000
Warrants outstanding									48,246
Class C Pre-Funded Warrants [Member]
2023 Public Offering [Line Items]
Issuance of common stock						336,400
Shares of common stock				336,400
Warrant exercise price, per share (in Dollars per share)	$ 14.34	$ 16	$ 3.3	$ 0.0001		$ 33.64
Purchase price, per share (in Dollars per share)			$ 0.0001	$ 4.8299
Warrants outstanding
Class C Common Stock Warrant [Member]
2023 Public Offering [Line Items]
Issuance of common stock				6,450,000			2,385,137
Shares issued, price per share (in Dollars per share)				$ 5.36
Warrants and rights expiration date				Feb. 14, 2028
Purchase price, per share (in Dollars per share)				$ 4.83			$ 5.36	$ 5.36		$ 5.36
Aggregate value of warrants (in Dollars)				$ 14,000,000
Warrants outstanding							487,160	487,160

Common Stock (Details) - Sche_2

Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance - shares	Sep. 30, 2023	Sep. 30, 2022	Jan. 25, 2022	Jan. 23, 2022
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	1,202,538	719,662
Shares available for future stock grants under the 2021 Equity Incentive Plan	1,202,538	719,662
Total common stock reserved for issuance	1,202,538	719,662
Public Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	300,332	300,332
Shares available for future stock grants under the 2021 Equity Incentive Plan	300,332	300,332
Total common stock reserved for issuance	300,332	300,332
Class A Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	73,905	73,905	73,905	73,905
Shares available for future stock grants under the 2021 Equity Incentive Plan	73,905	73,905	73,905	73,905
Total common stock reserved for issuance	73,905	73,905	73,905	73,905
Class A Placement Agent Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	10,347	10,347
Shares available for future stock grants under the 2021 Equity Incentive Plan	10,347	10,347
Total common stock reserved for issuance	10,347	10,347
Class B Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	238,095	238,095
Shares available for future stock grants under the 2021 Equity Incentive Plan	238,095	238,095
Total common stock reserved for issuance	238,095	238,095
Class B Placement Agent Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	16,667	16,667
Shares available for future stock grants under the 2021 Equity Incentive Plan	16,667	16,667
Total common stock reserved for issuance	16,667	16,667
Class C Common Stock Warrant [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	487,160
Shares available for future stock grants under the 2021 Equity Incentive Plan	487,160
Total common stock reserved for issuance	487,160
Rollover Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	4,738	4,738
Shares available for future stock grants under the 2021 Equity Incentive Plan	4,738	4,738
Total common stock reserved for issuance	4,738	4,738
Rollover Restricted Stock Units Member
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	3,006	7,290
Shares available for future stock grants under the 2021 Equity Incentive Plan	3,006	7,290
Total common stock reserved for issuance	3,006	7,290
Share-Based Payment Arrangement, Option [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	35,005	10,058
Shares available for future stock grants under the 2021 Equity Incentive Plan	35,005	10,058
Total common stock reserved for issuance	35,005	10,058
Dilutive shares [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	1,169,255	661,432
Shares available for future stock grants under the 2021 Equity Incentive Plan	1,169,255	661,432
Total common stock reserved for issuance	1,169,255	661,432
Stock grants under two thousand twenty one Equity Plan [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance [Line Items]
Shares reserved for issuance	33,283	58,230
Shares available for future stock grants under the 2021 Equity Incentive Plan	33,283	58,230
Total common stock reserved for issuance	33,283	58,230

Common Stock (Details) - Sche_3

Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) - $ / shares	Sep. 30, 2023	Feb. 13, 2023	Dec. 31, 2022	Sep. 30, 2022	Jul. 28, 2022	Jan. 25, 2022
Public Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	$ 402.5			$ 402.5
Class A Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	115.15		$ 115.15	115.15		$ 115.15
Class A Placement Agent Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	115.15		115.15	115.15
Class B Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	21		21	21	$ 21
Class B Placement Agent Common Stock Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	26.25		$ 26.25	26.25	$ 26.25
Class C Common Stock Warrant [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	5.36	$ 4.83		5.36
Rollover Warrants [Member]
Common Stock (Details) - Schedule of Total Shares of Common Stock Reserved for Issuance (Parentheticals) [Line Items]
Warrant exercise price, per share	$ 93.8			$ 93.8

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of Stock Options Activity - Share-Based Payment Arrangement, Option [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation (Details) - Schedule of Stock Options Activity [Line Items]
Shares Outstanding, Ending Balance	35,005	9,581
Weighted-average Exercise Price, Ending Balance	$ 9.6	$ 31.91
Weighted-average Remaining Contractual Term (Years), Ending Balance	8 years 2 months 12 days	3 years 6 months
Shares, Exercisable	32,514	5,590
Weighted-average Exercise Price, Exercisable	$ 6.58	$ 19.71
Weighted-average Remaining Contractual Term (Years), Exercisable	8 years 2 months 12 days	2 years 7 months 6 days
Shares, Granted	25,424	15,708
Weighted-average Exercise Price, Granted	$ 1.19	$ 38.57
Shares, Exercised
Weighted-average Exercise Price, Exercised
Shares, Expired and forfeited		6,127
Weighted-average Exercise Price, Expired and forfeited		$ 49

Stock-Based Compensation (Det_6

Stock-Based Compensation (Details) - Schedule of Assumptions used in Estimating Fair Value of Stock Options - Share-Based Payment Arrangement, Option [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Stock-Based Compensation (Details) - Schedule of Assumptions used in Estimating Fair Value of Stock Options [Line Items]
Volatility	126%	96.50%
Expected term (years)	5 years 10 days	5 years
Risk-free interest rate	3.09%	2.27%
Expected dividend yield	0%	0%

Stock-Based Compensation (Det_7

Stock-Based Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	$ 32,096	$ 40,675	$ 123,626	$ 268,755
General and administrative stock-based compensation expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	29,600	13,016	116,138	144,824
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	2,496	27,659	7,488	123,931
Restricted Stock Units (RSUs) [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	22,384	23,928	67,150	108,040
Restricted Stock Units (RSUs) [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	1,898	6,021	5,694	39,608
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	7,216	(10,912)	48,988	36,784
Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
stock-based compensation expense	$ 598	$ 21,638	$ 1,794	$ 84,323

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Rollover Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	115%	115%
Expected term (years)	6 years	6 years
Risk-free interest rate	0.85%	0.85%
Expected dividend yield	0%	0%
Class A Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	47%	47%
Expected term (years)	5 years	5 years
Risk-free interest rate	1.54%	1.54%
Expected dividend yield	0%	0%
Class A Placement Agent Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	47%	47%
Expected term (years)	5 years	5 years
Risk-free interest rate	1.54%	1.54%
Expected dividend yield	0%	0%
Class B Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	144%	144%
Expected term (years)	5 years	5 years
Risk-free interest rate	2.69%	2.69%
Expected dividend yield	0%	0%
Class B Placement Agent Common Stock Warrants [Member]
Schedule of Fair Value of Warrants Estimated Using Black-Scholes Option Pricing Model [Line Items]
Volatility	144%	144%
Expected term (years)	5 years	5 years
Risk-free interest rate	2.69%	2.69%
Expected dividend yield	0%	0%